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 The polyglutamine (polyQ) diseases, including Spinocerebellar Ataxia type 3 
(SCA3), are inherited neurodegenerative diseases caused by glutamine-encoding CAG 
expansions in disease genes. All polyQ diseases exhibit accumulation and aggregation of 
the disease protein in affected brain regions, yet central questions remain regarding the 
pathogenesis of these untreatable disorders, including which factors can influence disease 
protein aggregation, the extent to which aggregation drives disease, and the processes by 
which aggregation might contribute to toxicity.  
My thesis addresses these questions in a novel knock-in mouse model of SCA3. 
Chapter 1 reviews central features of polyQ disease, the use of knock-in mouse models to 
study polyQ disease, and aspects of SCA3. Chapter 2 provides the materials and methods 
used for the dissertation. Chapter 3 describes the generation and characterization of a 
SCA3 knock-in mouse model. SCA3 knock-in mice show striking mutant ATXN3 
accumulation and aggregation in brain. This accompanies aberrant splicing of the mutant 
Atxn3 transcript, emulating an important feature of the human ATXN3 transcript. Chapter 
4 further explores how alternative Atxn3 splicing influences aggregation in a “variant” 
SCA3 knock-in mouse that exhibits minimal aggregate pathology. Using various mouse 
models I explore the relationship between mutant ATXN3 aggregation and transcriptional 
alterations in the pons, a susceptible brain region. Chapter 5 concludes the dissertation 
with thoughts regarding moving forward with this work. 
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This thesis establishes the utility of SCA3 knock-in mice for studying early 
molecular pathogenic events and provides evidence supporting a critical role for 
alternative splicing in influencing disease protein aggregation. The results further suggest 
a molecular link between the process of ATXN3 aggregation and transcriptional 
dysregulation in the brain. Together, these findings support a pathogenic role for disease 






















Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease 
(MJD), is a hereditary neurodegenerative disorder caused by a glutamine-encoding CAG 
repeat expansion in the ATXN3 gene. This dissertation utilizes, among a diverse set of 
resources, novel knock-in mouse models of disease to study the intriguing relationship 
between alternative splicing of the disease transcript, disease protein aggregation, and 
transcriptional alterations in the brain. SCA3 also belongs to a larger group of 
polyglutamine (polyQ) diseases caused by CAG expansions in different genes. Despite 
considerable advances in the last two decades in understanding the molecular 
pathogenesis of these diseases, central questions remain unresolved. In this introductory 
Chapter, I review the central features of polyQ disease, the role of knock-in mouse 
models in polyQ disease research, and the clinical and molecular features of SCA3. This 
overview seeks to put into context the dissertation work on SCA3 disease pathogenesis 
described in subsequent chapters.  
1.1 Toward understanding the polyglutamine diseases  
 
1.1.1 The polyglutamine disease genes and proteins 
 
Abnormally expanded CAG nucleotide repeat expansions in coding regions of 
distinct genes are responsible for a group of neurodegenerative disorders known as the 
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polyglutamine (polyQ) diseases. The CAG expansion in the X-linked androgen receptor 
gene AR was first identified in 1991 as the cause of spinal and bulbar muscular atrophy 
(SBMA) (1). SBMA has since been joined by eight other polyQ diseases caused by CAG 
expansions in different genes. These diseases include Huntington disease (HD), the 
Spinocerebellar Ataxias (SCA) types 1, 2, 3, 6, 7, 17, and dentatorubralpallidoluysian 
atrophy (DRPLA). With the exception of SBMA, which is an X-linked disease, the polyQ 
diseases are autosomal dominantly inherited.  
Despite sharing CAG repeat expansions, the polyQ disease genes and their 
encoded proteins are diverse. Table 1.1 lists the polyQ diseases and highlights some of 
these features. One point of diversity is the number of different exons/introns in polyQ 
disease genes, with the CAG repeat located in different exons. Consequently, the location 
of the polyQ tract in the different disease proteins differs greatly. For example, the polyQ 
tract resides close to the N-terminus of HTT in HD and close to the C-terminus in 
ATXN3 in SCA3, while some polyQ tracts are found towards the center of their 
respective disease protein. Table 1.1 also shows the relative size of the polyQ proteins by 
primary amino acid length, with HTT being the largest (>300 kD) and ATXN3 and TBP 
(disease protein in SCA17) the smallest (<50 kD), with other polyQ disease proteins 
being intermediate in length.  The size range of polyQ expansions and threshold for 
disease-causing repeat length also varies. For example, while expansions greater than 
approximately 60 CAG repeats in ATXN3 cause SCA3, repeat lengths as small as 20 in 
CACNA1A cause SCA6; the other diseases show threshold lengths in the mid to upper 
30s. Finally, the functions of the polyQ disease proteins are diverse and distinct. While 
several polyQ proteins are associated with transcriptional function, they are rarely linked 
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to the same cellular pathways. The fact that distinct clinical disorders are caused by 
similar CAG expansions in different genes likely reflects one or more of these several 
points of diversity.  
Nonetheless, the shared CAG expansion still leads to important common features 
among the different polyQ diseases. The polyQ diseases are generally late-onset disorders 
associated with selective dysfunction and degeneration of the nervous system, even 
though the polyQ disease proteins are expressed throughout the body. The affected 
regions of the CNS differ among the polyQ diseases, yet some brain regions like the 
cerebellum and brainstem are particularly vulnerable, as indicated by seven of the nine 
known polyQ disorders showing prominent brainstem and cerebellar degeneration (2, 3). 
All polyQ diseases are characterized by the misfolding, accumulation, and aggregation of 
the disease protein in the nervous system, which I will further discuss below. These 
shared features between polyQ diseases suggest common disease mechanisms. Thus, the 
study of a specific polyQ disorder could shed light on others. Conversely, studying 
individual polyQ diseases may help solve the puzzle of selective regional vulnerability 
among the polyQ diseases.  
Protein misfolding and aggregation is not a unique feature of polyQ diseases. A 
number of other neurodegenerative diseases, including Alzheimer disease (AD), 
Parkinson Disease (PD), and amyotrophic lateral sclerosis (ALS) are characterized by the 
accumulation of different aggregated disease proteins in the nervous system (4). In most 
affected individuals, these diseases occur sporadically with no known genetic mutation or 
family history, though all of them can be caused by specific mutations in the respective 
disease proteins. While hundreds of thousands of individuals with polyQ disease may 
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benefit from an effective therapy, the polyQ diseases are rare compared to AD and PD. 
Nonetheless, the polyQ diseases serve as a simpler paradigm to study the relationship 
between protein misfolding, aggregation, and neurodegeneration. A better understanding 
of these relationships could provide insight on the neurodegenerative processes of more 
common diseases.  
1.1.2 Disease protein misfolding and aggregation: central to pathogenesis? 
   
Despite their monogenic inheritance pattern, polyQ diseases have a complex 
etiology involving widespread cellular effects, and disease pathogenesis can be 
influenced by various factors along the pathogenic cascade. Figure 1.1 depicts a 
simplified model of the path from expanded CAG repeat to neurodegeneration that 
includes disruption of several important cellular processes. This figure also highlights 
some of the pathogenic properties that may be exerted directly by mutant RNAs and 
proteins and lists several factors that can modify disease pathogenesis. At the DNA level, 
the length of the repeat and its stability within tissues are important factors that influence 
disease onset and severity. The transcribed RNA itself can potentially exert toxicity by 
sequestering RNA binding proteins, or the mutant disease transcript can be misspliced to 
produce more toxic isoforms. MicroRNAs can influence the stability or translation of the 
disease transcript. The misfolded and aggregated polyQ protein can misbehave in 
different ways to exert toxicity: it can engage in altered interactions with its normal 
binding partners, initiate new toxic interactions with other proteins, sequester important 
cellular factors, and alter/impair the native function of the disease protein. The toxic 
properties of a polyQ disease protein can be further influenced by other factors including 
the differing solubility of alternate disease protein isoforms, post-translational 
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modifications (e.g. proteolytic processing), and protein clearance pathways (e.g. 
chaperones and autophagy). The impaired clearance of the aggregated polyQ protein 
leads to its accumulation in the nervous system and in different cellular compartments, 
especially in the nucleus of neurons. Eventually, these proteotoxic processes lead to 
several possible downstream consequences, including disrupted transcriptional processes, 
organelle (e.g. mitochondria) dysfunction, ion channel/electrophysiological dysfunction, 
DNA damage with apoptotic pathway activation, altered protein quality control systems, 
among others. Ultimately, these processes lead to neuronal and non-neuronal 
dysfunction, disrupted neuro-circuitry, and neurodegeneration. While this chapter will not 
cover all the different aspects of polyQ disease introduced here, it will touch on certain 
important features that are relevant to the work presented later in the dissertation.  
A key early event and potential central mediator of disease processes is disease 
protein aggregation. Pioneering studies examining polyQ disease brains immunostained 
for the mutant protein revealed large intraneuronal inclusions in various brain regions (5, 
6). These inclusions co-immunostain for ubiquitin, molecular chaperones, and 
proteasome subunits, suggesting that cellular degradation machinery is engaged in the 
clearance of the disease protein (7, 8). The presence of inclusions of the disease protein in 
the nervous system is now recognized as a pathologic hallmark of polyQ diseases. 
Importantly, longer CAG repeat lengths in the disease gene are associated with earlier 
disease-onset, in some cases accelerated disease progression, and increased disease 
protein aggregation in the brain (9–11). In conjunction with the dominantly-inherited 
nature of all but one polyQ disease, these early findings led to the hypothesis that polyQ 
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expansions cause disease through toxic gain-of-function mechanisms exerted by disease 
protein misfolding and aggregation.  
A large body of evidence establishes a strong association between polyQ disease 
aggregation and toxicity in numerous models of disease. Overexpression of the polyQ 
protein or polyQ-containing fragments recapitulate aggregate formation and toxicity in 
various systems, including cell culture, yeast, worms, fruit flies, and mice. Studies in 
these models established that altering protein quality control factors implicated in the 
proper folding or clearance of misfolded proteins, namely molecular chaperones and 
associated proteins, could affect aggregation and toxicity (12–21). This prior work 
includes previous studies in our lab showing that the loss of CHIP, a ubiquitin ligase that 
interacts with molecular chaperones, accelerates aggregation and lethality in a transgenic 
mouse model of SCA3 (16). Conversely, overexpression of specific chaperones or CHIP 
can reduce aggregation and disease-associated phenotypes (12, 18, 22).  
 Just as the length of the polyQ tract can alter disease protein solubility and 
toxicity, so too can the sequence of the disease protein outside the polyQ tract. For 
example, early studies established that fragments of polyQ disease proteins are highly 
aggregate-prone and toxic in cell culture and mouse models, suggesting a “toxic fragment 
hypothesis” (23–26). Caspase and calpain proteases are primary suspects in driving 
polyQ disease protein cleavage, including in SCA3 and HD (27–31). Recent studies have 
shown in mouse models of SCA3 that increasing or decreasing the levels of calpastatin, 
an endogenous inhibitor of calpain, respectively attenuates or accelerates ATXN3 
aggregation and disease-associated phenotypes (32, 33). These findings underscore the 
importance of the protein sequence that harbors the polyQ tract (i.e. protein context) in 
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polyQ disease and provide additional correlative evidence between polyQ protein 
aggregation and disease pathogenesis.  
Several studies, however, called into question the role of aggregation in disease 
pathogenesis and suggested instead benign or even protective roles for aggregates. This 
debate is reviewed by Todd and Lim (34). Initial observations of polyQ disease brain 
pathology showed that the presence of inclusions in disease brain did not correlate 
(directly or inversely) with the regions most affected in disease (35–37). A landmark 
study by Arrasate and colleagues used automated microscopy to longitudinally examine 
neurons overexpressing a polyQ-containing fragment of mutant HTT and found that 
neurons that formed large HTT inclusions survived longer than those that did not (38). 
Further mismatch between aggregation-pathology and behavior phenotypes in mouse 
models raised questions on the role of aggregation in disease. A mouse model of HD 
expressing a mutant HTT fragment exhibited widespread neuronal inclusions but no 
behavioral phenotype (39) and, conversely, a transgenic mouse model of SCA3 exhibits a 
motor phenotype in the absence of detectable aggregate pathology (40). While 
chaperones could rescue toxicity in different disease models as mentioned above, a study 
by Chafekar et al showed that activated Hsp70 solubilizes aggregated polyQ proteins and 
increased toxicity (41). Together, studies have raised understandable concerns that polyQ 
aggregation may not necessarily represent a pathogenic disease process. 
The potential disconnect between polyQ disease protein aggregation and toxicity 
may stem from the different toxic properties associated with different polyQ aggregate 
species. It is now generally accepted that microscopically visible polyQ protein 
inclusions are unlikely to be directly neurotoxic, but increasing evidence suggests the 
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polyQ protein may still exert toxicity through misfolded monomeric or oligomeric 
species (11, 42, 43) (Figure 1.2). Nagai et al demonstrated that purified misfolded 
monomers of polyQ expanded protein in a -sheet conformation can induce toxicity in 
cell culture (44).  Automated longitudinal microscopy also revealed that the binding of an 
antibody that recognizes specific misfolded conformers of the polyQ monomer correlated 
with neuronal death (45, 46).  Legleiter et al. have proposed that misfolded monomers 
and oligomers adopt multiple conformations and can access or initiate several gain-of-
function interactions which may be toxic (11). In contrast, polyQ proteins sequestered 
into aggregates would not be able to exert these toxic properties.  
While the toxicity of different conformers has been demonstrated in vitro, directly 
isolating and demonstrating the relative toxicity of different polyQ species in vivo 
remains challenging. To support the potentially differing roles of aggregate species in 
vivo, overexpressing p62 improved motor symptoms in a mouse model of SBMA with a 
concomitant increase in the number and size of AR inclusions in the spinal cord (47). 
These mice also showed decreased monomeric and oligomeric AR detected 
biochemically (47).  
 In summary, the extent to which aggregation propensity of the polyQ disease 
protein directly drives pathogenesis in vivo remains debated. While overexpressing 
chaperones, protease inhibitors, or other factors can reduce aggregation and toxicity, 
these broad-acting factors may exert beneficial effects indirectly. Work presented in this 
dissertation avoids this potential pitfall by demonstrating that expressing different mutant 
ATXN3 isoforms with the same polyQ tract length, but differing solubility, leads to 
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marked differences in aggregate formation in vivo and subsequent molecular events, 
particularly transcriptional changes.  
1.1.3 Transcriptional dysregulation and gene expression profiling in polyQ disease 
 The mechanisms that drive polyQ toxicity remain the subject of investigation, but 
key observations support a critical role for nuclear localization of the disease protein. 
Firstly, a central feature of all polyQ diseases is the nuclear concentration and 
aggregation of the disease protein in neurons. Secondly, SBMA preferentially affects 
males due to androgen dependent effects of the polyQ-expanded AR protein that requires 
nuclear residence, and this is supported by mouse models of SBMA. Only male mice 
carrying mutant AR develop motor behavior symptoms, which diminish with castration 
(48) or by removing nuclear localization signals from AR (49). Other studies have added 
nuclear localization/export signals to the mutant polyQ proteins in mouse models, 
including for HD(50), SCA1(51), and SCA3 (52), which preferentially show disease 
phenotypes when there is nuclear localization of the disease protein. These observations 
and the fact that transcriptional roles have been suggested for all polyQ proteins have led 
to the major hypothesis that transcriptional dysregulation contributes to disease 
pathogenesis (53) 
PolyQ expansions can alter transcriptional activities of the disease protein through 
different means, as recently reviewed by Mohan et al (54).  The polyQ expansion in HTT 
alters its interactions with or sequesters important transcription factors, including CREB-
binding protein (55, 56), Sp1 (57), or REST/NRSF (58). PolyQ expansions can alter 
transcription factor activities of the disease protein, as seen with AR in SBMA (59). AR’s 
ability to bind DNA is also required for mutant AR-induced toxicity in flies (60).  The 
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polyQ expansion in ATXN1 alters its interaction with different transcriptional factors, 
including the transcriptional repressor Capicua, and this leads to both loss- and gain-of-
function changes in target genes (61, 62).  Direct alterations in transcription-associated 
functions of expanded polyQ have also been observed in SCA7 (63) and SCA17 (64, 65).  
A useful way to assess transcriptional dysregulation is through gene profiling of 
affected human disease tissue and equivalent brain regions in mouse models of disease. 
Transcriptional profiling has been a powerful tool in identifying early molecular 
correlates to disease including dysregulated transcriptional pathways (66). Extensive 
transcriptional profiling in HD, as reviewed by Seredenina and Luthi-Carter (67), has 
revealed numerous perturbed biological pathways associated with mutant HTT 
expression: neurotransmitter signaling, calcium signaling and homeostasis, 
mitrochondrial function, and others. Transcriptional profiling of SCA17 recently 
identified that the loss of an important age-related transcription factor, MANF, could 
accelerate disease (68). Transcriptional profiling in SCA1 and SCA7 revealed robust 
downregulation of Igfbp5 to indicate possible converging pathways in SCAs (69). 
Profiling of DRPLA mouse models has shown CAG repeat length- and age-dependent 
transcriptional alterations in pathways associated with calcium-dependent signaling and 
neuropeptide signaling (70). Profiling of muscle tissue in mouse models of SBMA has 
indicated alterations in mitochondrial and metabolic pathways (71, 72).  
In short, gene expression profiling has implicated possible transcriptional 
pathways in the pathophysiology of multiple polyQ diseases. Characterizing these 
disrupted transcriptional networks in polyQ disease could help move the field toward 
therapies by either identifying critical factors (e.g. transcription factors) that elicit 
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observed transcriptional changes or by identifying pharmacologically accessible 
downstream targets (e.g. ion channels) that exacerbate neuronal dysfunction. At a 
minimum, gene expression profiles provide a sensitive and early readout of disease-
associated processes in vivo (73). Kuhn et al showed that expression profiles of seven 
different HD mouse models showed good concordance with profiles of human HD 
caudate (74), supporting the view that expression profiling of mouse models can provide 
insight into human disease pathogenesis. However, agreement between human disease 
tissue and animal model expression profiling cannot be assumed for all disease models, 
and confidence in the data set of any profiling experiment improves with validation of 
one or more predicted changes in human disease tissue. 
To date, polyQ disease gene expression profiles largely have utilized microarray 
technology. The advent of next-generation sequencing technology, such as RNA-
sequencing, has greatly increased the sensitivity of detecting altered transcripts, and 
performing RNA sequencing today is equally if not more cost-effective than performing 
microarrays. Moreover, continually improving bioinformatic analytical tools allow 
scientists to better characterize transcriptional networks and the processes that might 
drive their disruption. Work in this dissertation utilizes RNA-sequencing to 
comprehensively identify transcripts associated with mutant ATXN3 aggregation.  
1.2 Knock-in mouse models of polyglutamine disease 
The ability to address important questions about polyQ disease pathogenesis 
hinges on the availability of appropriate model systems. The range of model systems in 
polyQ disease research is vast, spanning from the in vitro characterization of purified 
disease protein (75) to the insertion of disease genes into non-human primates (76). Each 
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disease model has advantages and disadvantages and can provide complementary 
information on different aspects of disease. Work in this dissertation extensively uses 
knock-in mouse models of disease, which are particularly suited to study early molecular 
pathogenic events in vivo under pathophysiological expression conditions. This section 
reviews the major aspects of knock-in mouse models and their utility in studying polyQ 
disease pathogenesis.  
1.2.1  Mouse models of polyQ disease and general features of knock-in mice 
  
The study of polyQ disease in vivo extensively utilizes mice, which are valuable 
for several reasons: 1) they breed quickly, allowing faster assessment of disease features, 
2) they are relatively easy to genetically manipulate compared to other vertebrate models, 
and 3) as mammals they exhibit good morphological and functional similarity to the 
human brain and its cellular components, including neurons, glia, other cell types, and 
functional circuitry. Modeling these diseases has been aided by the fact that transgenic 
overexpression of mutant polyQ proteins from human mutant cDNAs often elicits robust 
neuropathological and behavioral changes in mice, consistent with the dominant 
inheritance of disease in humans. Even the transgenic insertion of a full-length human 
disease gene through a bacterial or yeast artificial chromosome (BAC or YAC) can lead 
to robust expression of the disease protein. Of course, mice cannot recapitulate every 
feature of disease in humans, who have more complicated nervous systems and harbor 
CAG mutations for decades before exhibiting symptoms. An unsolved challenge in the 
polyQ field has been defining the best type of mouse model and the most critical features 
of mouse models that will best predict the success of therapeutic interventions in humans. 
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Nonetheless, mouse models of polyQ disease have been useful in exploring the properties 
and effects mutant polyQ proteins expressed in a mammalian nervous system.  
Among the possible types of mouse models are knock-in mouse models of polyQ 
disease. Knock-in models take advantage of the presence of closely related orthologues to 
human disease genes in mice. Knock-in mouse models of polyQ disease, in which the 
endogenous CAG repeat within the gene of interest is expanded, represent a genetically 
precise in vivo approximation of human polyQ disease. In contrast to overexpression 
mouse models, knock-in mice express the mutant transcript and protein at physiological 
concentrations, which are regulated by endogenous murine regulatory factors and 
elements. Some polyQ knock-in mice exhibit key features of human disease, including 
neuropathological and behavioral abnormalities. By being genetically precise and within 
the animal genomic and protein contexts, knock-in mice allow scientists to identify the 
consequences, for a given  mutant protein, of loss-of-function, disrupted native 
interactions, and novel interactions, and to  identify cis- and trans-acting gene regulatory 
elements that control the mutant gene’s expression.  
Importantly, the physiological nature of knock-mice makes them well suited to 
investigate early molecular changes associated with expression of a disease gene in the 
brain. To date, several disease-modifying polyQ disease therapeutic trials have been 
performed in symptomatic subjects and so far have failed (77–79). Earlier 
presymptomatic interventions may be necessary for improved outcomes. Therefore, 
defining early molecular changes in disease using knock-in mouse models may be the 
key to identifying early presymptomic biomarkers of disease processes en route to 
finding effective therapies.  
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Knock-in mouse models, however, present several caveats and challenges. The 
most evident drawback is that most knock-in mice do not exhibit robust behavioral 
abnormalities even at relatively advanced age. The exception is in knock-in mouse 
models expressing hyper-expanded repeats (that is, well beyond known human disease 
repeat lengths or so long as to cause an atypical infantile onset disease in humans). 
Hyperexpanded repeats may not be the most appropriate models of the common, adult-
onset form of disease. In addition, subtle differences between mouse and human genes 
and proteins can pose a challenge for designing and testing therapeutic targets that are 
specific to the human disease gene or protein. The mouse and human proteins also may 
behave differently when an expanded polyQ tract is inserted. These considerations 
underscore the importance, when using mouse models to identify disease-related changes, 
of striving to validate critical findings in human disease tissue. One could argue knock-in 
mice provide the best prediction of early molecular changes, since they most closely 
mimic the genetic cause of the disease in humans. However, such a comparative analysis 
has not been systematically performed across the different polyQ disease mouse models 
and the respective diseases they model.  
1.2.2 Lessons from knock-in mouse models of polyQ disease 
The greatest number of available knock-in mice is for HD (Table 1.2) and, with 
the exception of DRPLA, all other polyQ diseases now have at least one knock-in mouse 
model available (Table 1.3). Table 1.3 includes two recently reported knock-in mouse 
models of SCA3, one of which was generated in our lab and is utilized throughout this 
dissertation. All published polyQ disease knock-in mice were generated through 
homologous recombination techniques to replace the endogenous murine CAG repeat 
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with a segment containing a long CAG repeat. Some knock-in mice were generated using 
a human exon with the expanded CAG tract to replace the mouse exon, resulting in a 
chimeric human/mouse exon. Other groups have simply expanded the endogenous CAG 
repeat in the mouse exon. All knock-in mouse models express the mutant polyQ protein 
and exhibit some degree of intraneuronal accumulation of the mutant protein, thus 
recapitulating a key early disease feature. Only a few knock-in mouse models with 
especially long CAG expansions exhibit behavioral phenotypes, and most do not show 
clear neurodegenerative changes.   
The study of knock-in mouse models of polyQ disease has been instrumental to 
understanding different aspects of disease pathogenesis including behavior of the mutant 
gene, transcript and protein, and their effects on downstream processes. To highlight a 
few key findings: Several polyQ disease knock-in mouse models exhibit intergenerational 
and somatic instability of the CAG repeat (80–82), and reducing repeat instability in HD 
knock-in mice correlates with reduced aggregation in the brain (83, 84); knock-in mice of 
HD and SCA6 have helped characterize alternative splicing of their respective disease 
transcripts (85, 86); SCA1 knock-in mice have paved the understanding of how polyQ-
driven alterations of native interactors, for example via a specific phosphorylation site, 
can affect disease pathogenesis (87, 88); Chua and colleagues recently altered 
SUMOylation sites in SBMA knock-in mice to demonstrate that functional recovery of 
expanded AR protein was associated with improved muscle function (72); a conditional 
knock-in mouse model of SCA17 helped identify critical age-associated factors and their 
contribution to disease (68); Finally, knock-in mice have been useful for pre-clinical 
testing of several novel therapies (89–92).  
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In general, knock-in mouse models have proved to be a valuable tool, but the 
concurrent use of other disease models is important to identify converging affected 
pathways or to confirm hypotheses. These additional models include transgenic mice that 
overexpress the human disease protein. Transgenic mice expressing the full-length 
disease gene containing all introns and exons can be especially useful for investigating 
disease gene splicing in vivo. The work in this dissertation uses multiple SCA3 mouse 
models and human tissues samples to strive for findings that have a high probability of 
occurrence in human disease. Ultimately, there is no perfect model of disease until we 
clearly identify predictive markers or interventions that translate directly from model to 
disease. Until then, a combinatorial and interdisciplinary approach with models for 
disease is most likely to bring us closer to therapies.  
1.3 Toward understanding spinocerebellar ataxia type 3  
The studies described here on SCA3 are motivated by several factors. Although 
SCA3 is among the most prevalent of the polyQ diseases, no SCA3 knock-in mouse 
model was published at the time my dissertation work began. The size of the SCA3 
disease gene, transcript, and protein are all fairly small, which allows straightforward 
visualization and manipulation of these elements in vivo. The function of the ATXN3 
protein is also well characterized, which facilitates investigation of both loss-of-function 
and gain-of-function contributions to disease. Together, these factors helped ensure my 
capacity to make important contributions toward understanding SCA3 pathogenesis. An 
improved understanding of SCA3 could benefit the substantial number of individuals 
affected by SCA3, as well as other polyQ diseases. The remainder of this introduction 
highlights some of the major clinical and pathogenic features of SCA3 and how this 
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dissertation aims to address critical questions on polyQ disease pathogenesis using SCA3 
knock-in mice.  
1.3.1 Clinical and pathological features of SCA3  
 
Several reports in the 1970s described an ataxic disorder in different families of 
Portuguese ancestry, particularly those of Azorean descent (93–96). The mysterious 
disease at the time went by different names such as nigro-spino-dentatal degeneration, 
striatonigral degeneration, or Azorean disease. The study of two different families with 
this ataxic disorder who were respective descendants of William Machado  and Antone 
Joseph led to the name Machado-Joseph disease (97). Geneticists in Europe in the 1990s 
had also designated what seemed to be a distinct hereditary ataxia as SCA3. The 
identification of the causative mutation in 1994 unified Machado-Joseph disease and 
SCA3 as one disorder that is now believed to be the most common dominantly inherited 
ataxia in the world (98, 99).    
Along with ataxia, SCA3 is clinically characterized by a constellation of signs and 
symptoms that can vary greatly among affected persons. These symptoms include speech 
difficulty, rigidity, spasticity, proptosis, ophthalmoplegia, eye movement and vision 
difficulties (100). Some affected individuals exhibit prominent Parkinsonism. SCA3 can 
be phenotypically classified into four subtypes, which are not clinically very helpful but 
demonstrate the heterogeneous presentation of disease (101). Increasing studies also 
recognize cognitive symptoms associated with SCA3 (102–104).  
Post-mortem analysis in SCA3 brain has shown prominent degeneration of the 
deep cerebellar nuclei, as well as various associated nuclei of the brainstem and spinal 
cord (2, 105). The pons is especially affected as signified by some of SCA3’s alternative 
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names: olivopontocerebellar degeneration and spinopontine atrophy. As such, work in 
this dissertation frequently examines molecular alterations in the pons. As described 
above, these brain regions exhibit large intraneuronal ATXN3 inclusions. Furthermore, 
large axonal ATXN3 inclusions can also be found along different fiber tracts, particularly 
in the brainstem (106). Degeneration is not prominent in the SCA3 cortex and 
hippocampus, but aggregate pathology in these regions has not yet been systematically 
assessed.  
1.3.2 The ATXN3 gene, splice isoforms, and aggregation 
 
 The genetic structure of the ~48 kb ATXN3 gene and the location of the CAG 
repeat in the 10
th
 exon are shown in figure 1.3. Also shown are the spliced full-length 
ATXN3 transcript, containing all 11 coding exons, and a schematic of the encoded 
protein. When the disease gene was initially cloned by Kawaguchi and colleagues, the 
cDNA and gene were reported to contain only 10 exons (98). Three years later another 
group identified the 11
th
 coding exon (107). Bettencourt et al reported up to 50 different 
ATXN3 splice isoforms in patient blood samples though how many of these are 
expressed in specific tissues is unknown (108). The splice isoform encoded by full-length 
transcript with 11 exons (ATXN3-11e) appears to be most abundantly expressed (109), 
but the relative abundance of different ATXN3 isoforms has not yet been clearly 
established. A fair portion of published work on SCA3 studies the first identified 10 exon 
(ATXN3-10e) isoform, including studies using SCA3 mouse models that overexpress this 
minor isoform (110).  
Different ATXN3 isoforms exhibit differences in solubility and their expression 
may influence disease pathogenesis. The ATXN3-10e transcript does not splice to exon 11 
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and instead retains intron 10, which encodes a more hydrophobic stretch at the C-
terminus. Our lab previously determined that the ATXN3-10e isoform is more 
aggregation-prone in cell culture (109). However, the extent to which the expression of 
different ATXN3 isoforms can drive differences in aggregation and pathogenesis in vivo 
has not been explored. A significant part of this dissertation aims to show that the 
expression of a mouse ATXN3-10e isoform markedly accelerates ATXN3 aggregation in 
vivo. 
1.3.3 ATXN3 as a deubiquitinating enzyme  
The full-length ATXN3 protein is a small deubiquitinase (~42 kD, ~355 amino 
acids) with an evolutionarily conserved, globular catalytic domain at the N-terminus (so 
called Josephin domain), and an unstructured, flexible C-terminus (Figure 1.3). The 
Josephin domain contains two ubiquitin binding sites and a catalytic cysteine at the 14
th
 
residue (not depicted). The unstructured C-terminus stretch of the full-length isoform 
contains three ubiquitin interacting motifs (UIMs) as depicted in figure 1.3.  
ATXN3 localizes diffusely throughout the cell, found in both the cytoplasm and 
nucleus, where it functions in protein surveillance pathways. Using its multiple UIMs and 
enzyme activity, ATXN3 binds and trims polyubiquitinated chains conjugated to 
proteins, particularly Ub chains containing four or more ubiquitin (111, 112). As a result 
of ATXN3’s broad substrate activity, ATXN3 knockout mouse brains exhibit elevated 
total levels of polyubiquitinated proteins (113, 114). Of note, the third UIM is encoded by 
exon 11 and is therefore missing in the ATXN3-10e isoform. this does not, however, lead 




The deubiquitinating role of ATXN3 has raised the intriguing possibility that its 
enzymatic activity may influence its own aggregation and disease pathogenesis. In 
support of this concept, a fly model of SCA3 showed that overexpressing wild-type 
ATXN3 protects against eye degeneration, and that this protection required ATXN3’s  
deubiquitinating activity (115). However, a protective effect of ATXN3 was not 
confirmed in mammalian models overexpressing wild-type ATXN3 (116, 117). Work in 
our lab by Dr. Li Zeng also found that knocking out endogenous ATXN3 did not alter 
disease progression in a knock-in mouse model of HD (118). ATXN3 does not seem to 
be an essential protein since ATXN3 knockout mice are healthy (113), suggesting that the 
toxicity of mutant ATXN3 predominantly arises from gain-of-function mechanisms. This 
does not, however, exclude the possibility that ATXN3’s function and polyQ-dependent 
dysfunction may influence disease pathogenesis and selective regional vulnerability. 
1.3.4 ATXN3 function and dysfunction in the nucleus 
ATXN3 plays an active role in the nucleus and mutant ATXN3 dysfunction in the 
nucleus may contribute to disease pathogenesis. ATXN3 can freely shuttle between the 
cytoplasm and nucleus (119) and concentrates in the nucleus with heat or oxidative stress 
(120). ATXN3 has been reported to act as a transcriptional co-repressor (121), and 
ATXN3 can work in concert with HDAC3 and NCor to repress transcription (122). 
Mutant ATXN3 is not as effective at this repression (122), which may lead to 
dysregulation of various target genes. ATXN3 also interacts with the transcription factor 
FOXO4 to upregulate superoxide dismutase 2 (SOD2), a protein that helps break down 
oxygen radicals (123). Mutant ATXN3 expression reduces SOD2 transcription, possibly 
increasing cellular vulnerability to oxidative stress (123). While ATXN3 has clear effects 
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on the transcription, the extent to which ATXN3 acts as a traditional transcription 
cofactor rather than as a deubiquitinase that regulates other transcription factors is 
unclear.  
Emerging evidence on the role of ATXN3 in DNA damage repair supports a role 
for impaired DNA repair in SCA3 pathogenesis (124). ATXN3 is well-known to interact 
with DNA repair-associated proteins, including RAD23A (125–127). Recently, mutant 
ATXN3 was shown to interact with and inhibit mammalian polynucleotide kinase 3’-
phosphatase (PNKP), an enzyme involved in DNA repair, leading to increased DNA 
damage and activated apoptotic pathways, which may drive cell death in disease (128, 
129). The authors further showed that induction of apoptotic pathways by mutant 
ATXN3 is mediated by the protein ataxia telangiectasia mutated (ATM) (129), an 
important DNA damage checkpoint component of the cell cycle that is mutated in a 
childhood onset form of ataxia. ATM mediates toxicity in models of HD, and its 
reduction can reduce mutant HTT-induced toxicity (130).  As other studies converge on 
DNA damage in polyQ diseases (131–133), disrupted nuclear processes continue to be a 
dominant theme in polyQ disease pathogenesis. 
1.4 Summary and aims of the dissertation 
SCA3, caused by a CAG repeat expansion in the ATXN3 gene, is likely the most 
common of the polyQ diseases with many unresolved questions regarding disease 
pathogenesis. Like other polyQ diseases, SCA3 appears to be predominantly mediated by 
toxic gain-of-function mechanisms, and emerging evidence implicates important roles of 
ATXN3 dysfunction in disease pathogenesis, particularly in the nucleus. However, the 
extent to which mutant polyQ protein aggregation contributes to disease pathogenesis is 
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still debated. To address this further, I sought to identify factors that modify mutant 
ATXN3 aggregation in a physiologically-relevant disease model.  
Current understanding of SCA3 pathogenesis benefits from various disease 
models that include worms, fruit flies, cell cultures, mice, and rats.  With the exception of 
patient fibroblasts and IPSC-derived neurons, prior models of SCA3 have overexpressed 
mutant disease protein and few had explored molecular pathogenesis of SCA3 under 
physiological expression conditions. This prompted me to approach the disease in a new 
way by using a knock-in mouse model. The generation of a knock-in model was started 
by Dr. Ginny Harris in the Paulson lab during her dissertation and completed by me.  
By approaching SCA3 using a novel and previously uncharacterized knock-in 
mouse model of disease, this dissertation addresses three main aims. The first aim is to 
demonstrate features of the SCA3 knock-in mouse model and its suitability for modeling 
disease, particularly with respect to disease protein aggregation and splicing of the 
disease transcript. Characterization of these mice led to the serendipitous identification of 
two separate lines of SCA3 knock-in mice that differentially express mutant Atxn3 splice 
isoforms, leading me to the second aim: determine the extent to which alternative splicing 
of Atxn3 contributes to ATXN3 aggregation. The third and final aim takes advantage of 
differences in aggregation in nearly identical SCA3 knock-in mice to address the extent 
to which mutant ATXN3 aggregation contributes to pathogenesis, assessed through 






Table 1.1: The diversity of polyglutamine (polyQ) disease genes, proteins, and 
function. Provided are the list of diseases, the exon in which the CAG repeat is expanded 
in disease, and the total number of exons in the gene. The diagrams show the relative size 
of the disease protein with the relative location of the polyQ expansion and includes the 
range of polyQ expansions known to cause disease. A general description of the protein’s 





Figure 1.1: Pathogenic factors from CAG expansion to disease. This simplified 
diagram shows the CAG repeat expansion leading to mutant RNA expression, mutant 
protein expression, and aggregation. Left, a list of properties directly exhibited by disease 
transcript and disease protein (and its aggregation) that may drive toxicity. Right, a list of 
factors at the level of the disease gene, transcript, and protein that can further influence 
pathogenesis. The misfolding and aggregation of disease protein may critically drive 
several downstream events listed below that lead to neurodegeneration. 
 
 
Figure 1.2: Basic model of polyQ disease protein aggregation. This diagram shows 
that the polyQ expanded protein has a tendency to misfold and aggregate, ultimately 
leading to the formation of microscopically visible puncta and inclusions in cells that are 
not directly toxic. Although a proteotoxic species in polyQ disease has not been clearly 
defined, increasing evidences suggests that monomeric and oligomeric states of disease 
protein may drive toxicity. Other intermediate species not depicted include amorphous 
aggregates, protofibrils, and fibrils. 
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HD knock-in mouse Neuropathological findings Behavioral changes Refs 
Q50 (HD/Hdh exon 1) No known abnormalities No known abnormalities (134) 
Q71 (HD/Hdh exon 1) No known abnormalities No known abnormalities (135) 
Q72-80  Increased nuclear localization neuronal 
intranuclear inclusions (NIIs), neuropil 
aggregates, axonal degeneration at >2 
years 
Aggression (~3 months), motor 
deficits at 4 months 
(136) 
Q77 (HD exon 1) Nuclear localization, NIIs, and 
neuropil aggregates 
Increased aggression >1 year (81, 137) 
Q80  Rare nuclear inclusions (up to 22 
months) 
Mild gait deficit at 10 months (138) 




Q92 (HD/Hdh exon 1) Nuclear localization and NIIs  in 
neurons 
Mild motor and memory deficits in 




(HD/Hdh exon 1) 
Nuclear localization and NIIs, gliosis, 
neuropil aggregates at 2 years 
Anxious/depressive-like behavior at 
4 months, memory deficits at 8 




(HD/Hdh exon 1) 
Nuclear localization and NIIs, neuropil 
aggregates. Reduced DARPP-32 in 
striatum, brain atrophy and neuronal 
loss 





(N-term Flag tag) 
Nuclear localization and NIIs (6 
months) 
Not reported (144) 
Q150-250 Q150-200: Nuclear localization and 
NIIs, neurpil aggregates, axonal 
degeneration, reduced neurotransmitter 
receptor binding, autophagic changes, 
gliosis in striatum 
Q250+: Reduced DARPP-32 in 
striatum, myelination defects 
Q150: Hindlimb dragging, clasping, 
and activity 4 months, motor deficits 
100 weeks, weight loss in 
homozygotes ~1.5 years 
Q200: Weight loss ~5 months, 
reduced grip strength ~1.5 years, 
motor deficits ~ 1 year 



















Neuronal intranuclear inclusions (NIIs) 
in spinal cord and skeletal muscle; 
neuromuscular pathology 
Decreased fertility,  androgen-
dependent early death, progressive 
motor deficits 
(48) 
SCA1 Q78 Not reported Mild motor incoordination in 
homozygous mice 
(80) 
Q154 Early nuclear accumulation and NIIs; 
synaptic deficits, Purkinje neuron 
atrophy and loss  
Weight loss, robust motor behavior 
and learning deficits 
(149) 
SCA2 Q42 NIIs in Purkinje neurons Motor deficits in homozygous mice 
(>18 months)  
(150) 
SCA3 Q82 Robust nuclear accumulation and NIIs; 
dystrophic neurites in hippocampus 
No detectable motor phenotype in 




ex 11)  
Nuclear accumulation, NIIs Mild motor behavior deficit in aged 
(>1 year) mice 
(152) 
SCA6 Q84 Mutant Cav2.1 aggregates in Purkinje 
neurons 
Progressive motor deficits (85) 
SCA7 Q266+  Neuronal accumulation and NIIs  Weight loss, visual and motor 
deficits, early death, robust motor 
behavior deficit 
(153) 
SCA17 Q105 Nuclear accumulation and NIIs, 
Purkinje neuron atrophy and loss 
Weight loss, moderate motor 
behavior deficits, Purkinje neuron 
loss 
(154) 
DRPLA N/A N/A N/A  






Figure 1.3: SCA3 mutant gene, transcript, and protein.   The ATXN3 gene is ~48 kb 
with 11 coding exons with large introns (shown to scale), with the CAG repeat in the 10
th
 
exon.  The ATXN3 protein is ~42 kD consisting of a globular Joseph domain and an 
unstructured C-terminal stretch containing the polyQ stretch (red) and three ubiquitin 
interacting motifs (UIM, orange).  ATXN3 primarily functions  as a deubiquitinating 
enzyme, but plays diverse roles in cellular pathways. The sizes of the ATXN3 gene, 











Chapter 2  
Materials and methods 
 This chapter provides information on the materials and methods used in both 
Chapters 3 and 4. The majority of the protocols given here are used in the work of both 
Chapters with few minor differences. Most of the information in this chapter has been 
published in Ramani et al (151). 
2.1 Generation of SCA3 knock-in mice 
The protocol described in this section was performed by Dr. Ginny Harris as part 
of her dissertation. A more comprehensive protocol is provided in her thesis (155). For 
the reader’s convenience, I have provided the protocol from our published report of the 
SCA3 knock-in mouse (151). The generation of these mice was aided by collaboration 
with Dr. Thomas Saunders and the Transgenic Animal Model Core 
(http://www.med.umich.edu/tamc/).   
Genomic murine Atxn3 DNA from a C57BL/6-tyr(c-2J) albino embryonic stem 
(ES) cell line (Millipore, Cat SCR011) was used to amplify a 4 kb upstream flanking arm 
derived from intron 9-10 and a 2.6 kb downstream flanking arm that spans exon 10. NotI 
and SalI restriction sites were engineered to flank the upstream flanking arm and a novel 
KpnI restriction site was engineered onto the 5’ end of the downstream flanking arm. The 
5’ flanking arm was then subcloned into pBY49a upstream of a FRT-PGK-Neo-FRT 
positive selection cassette. The 3’ flanking arm was subcloned into pBluescript SK(-) and 
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the CAG repeat was expanded using a modified QuickChange approach (156). Briefly, a 
human expanded CAG template (At3-Q129-GFP and At3-Q166-GFP) was amplified 
with partially complementary primers to generate an expanded (CAG)n “megaprimer” 
flanked by murine genomic sequence. This double-stranded megaprimer was used to 
insert an expanded (CAG)n repeat into the Atxn3 gene using the QuickChange 
Mutagenesis method (Stratagene). One clone generated was chosen for additional repeat 
expansion through splicing by overlap extension (157). We inserted the 3’ flanking arm 
from one clone of the megaprimer expansion series, which contained a Q3KQ82-
encoding expansion, into the targeting vector between the FRT-PGK-Neo-FRT positive 
selection cassette and the PGK-TK negative selection cassette, using KpnI and EcoRI 
restriction sites.  
The complete targeting vector was purified with NdeI and electroporated into 
Bruce4.G9 ES cells (158).  G418 and ganciclovir selection were used to enrich for ES 
cell colonies with the positive selection cassette and loss of the negative selection 
cassette. Each colony was screened for homologous recombination and CAG repeat 
expansion by PCR- and Southern blot-based strategies. ES cell clones containing the 
expansion and confirmed to be sufficiently euploid were microinjected into homozygous 
albino B6(Cg)-Tyr<c-2J>/J blastocysts. Microinjected blastocysts were introduced then 
into the uterine horns of pseudopregnant female mice. Chimeras were crossed to albino 
B6(Cg)-Tyr<c-2J>/J mice, and all black pups were assayed for germline transmission of 
the knock-in allele by PCR.   
For in vivo excision of the FRT-site flanked positive selection cassette, F1 
heterozygous knock-in animals were crossed with homozygous FLP recombinase 
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transgenic mice driving FLPe expression under the human -actin promoter (Jackson 
Laboratories, strain B6.Cg-g(ACTFLPe)9205Dym/J). F2 mice positive for the Q82 
knock-in expansion were crossed with C57BL/6 mice (Jackson Laboratories) to remove 
the FLPe transgene and outbred for at least four generations. Homozygous Q82/Q82 mice 
were generated and sequenced across the FRT site to ensure removal of the neomycin 
cassette and identify the remaining sequences in intron 9 (Figure 2.1)  
2.2 Animals and ethical use 
YAC-84Q and YAC-15Q mice (159) and ATXN3 knockout mice (120) are 
described previously. Mice used here are available from Jackson Laboratories including 
YAC-84Q mice (B6;CBA-Tg(ATXN3*)84.2Cce/IbezJ), Q82/Q6 mice (B6(Cg)-
Atxn3tm1Hlp/J), and  Nestin-Cre mice (B6.Cg-Tg(Nes-cre)1Kln/J). The Nestin-Cre mice 
were kindly provided by Corinne Weisheit of Dr. William Dauer’s lab (University of 
Michigan). All mice are maintained by veterinarians and animal care staff from the 
University of Michigan Unit for Laboratory Animal Medicine (ULAM). All 
manipulations and handling were performed in accordance with guidelines of the 
University of Michigan Committee on Use and Care of Animals.  
2.3 Genotyping and CAG repeat sizing 
DNA was extracted from clipped mouse tails using a DNeasy Tissue kit (Qiagen) 
and used for genotyping by PCR. Primers flanked the endogenous CAG repeat of exon 
10 of Atxn3 (see section 2.8 for primers). The PCR conditions are as follows: 95 deg C/2 
min, 30 cycles of 95 deg/30s, 51degC/30s, 72degC/1m, 1 cycle 72degC/10min. Products 
were run on a 1.5% agarose gel and visualized with ethidium bromide. Purified tail DNA 
was submitted for CAG repeat sizing to Laragen, Inc. (Culver City, CA, USA).  
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2.4 Tissue lysate preparation, SDS-PAGE, SDS-agarose, and western 
blot analyses 
Tissue lysates were prepared as previously described (16) with minor 
modifications. Briefly, frozen tissue was homogenized in 10 vol RIPA + protease 
inhibitor (PI) cocktail containing RIPA buffer (50 mM Tris–HCl pH 7.4, 150 mM sodium 
chloride, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40) and protease inhibitors 
(Complete Mini tablets, Roche). Homogenates were centrifuged at 1500g for 15 min at 4 
deg C, and supernatants (soluble fraction) was transferred to a new tube and assayed for 
protein concentration using bicinchoninic acid (Pierce). The soluble fractions were 
diluted to a final concentration of 4 g/l in RIPA + PI + loading buffer (from 6X 
concentration of 0.35 M Tris-HCl, 10.3% SDS, 36% glycerol, 0.6 M dithiothreitol, and 
12% bromophenol blue), and boiled for 5 min. Samples were separated by 10%, 3% 
SDS-PAGE, or 2% SDS-Agarose (with 0.1% SDS), transferred onto polyvinylidene 
fluoride membrane (PVDF), and blotted as previously described (16). The 3% gel was 
transferred onto PVDF using the BioRad TransBlot SD semi-dry apparatus on 10V for 30 
min. 
For an alternative method for detecting high molecular weight ATXN3 aggregates 
(Chapter 4 only), a mouse brain hemisphere was homogenized in 1 ml RIPA + PI, 
sonicated briefly, and centrifuged at 12,000g for 20 min. The supernatant was saved and 
assayed for protein concentration. 1 mg of protein was then incubated overnight in 1 l of 
1H9 antibody + 20 l protein A beads (Life Technologies). The protein A beads were 
then pelleted, washed, eluted by boiling 5 min in 2x loading buffer,  resolved on a 3-12% 
Tris-acetate gel, transferred to PVDF, and blotted with anti-MJD.  
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For work in Chapter 4, human disease brainstem tissues from three Alzheimer’s 
disease and three SCA3 cases were kindly provided by the University of Michigan Health 
System Brain Bank. Roughly 0.5 cm
3
 of brain stem tissue was used for western blot 
analysis using the protocol described above.  
Antibodies: 1H9 1:2000 (MAB5360, Millipore), anti-MJD 1:10,000 (160), -
tubulin 1:5000 (Cell signaling), ACY3 1:2000 (Proteintech).  
2.5 Immunohistochemistry, immunofluorescence, and scoring ATXN3 
accumulation 
Mice were transcardially perfused with chilled PBS and the brains removed. One 
hemisphere was fixed in 4% paraformaldehyde at 4 deg C for 48 hours and the other 
hemisphere was frozen on dry ice and stored in -80° C for biochemical experiments. 
Fixed brains were transferred to 30% sucrose in 0.1M phosphate buffer for at least 48 
hours at 4 deg C. Brains were then serially sectioned and stained as previously described 
(16). Immunofluorescent images were taken by Zeiss LSM 510-META Laser Scanning 
Confocal Microscope at the University of Michigan Microscopy & Image Analysis Core.   
Antibodies include anti-ataxin 3 clone 1H9 1:1000, anti-MJD 1:5000, anti-RTN3 
R458 1:2000 (kindly provided by Riqiang Yan, Cleveland Clinic, Cleveland, OH, USA), 
anti-MAP2 1:2000 (M4403, Sigma), SMI32 1:2000 (NE1023, Calbiochem).  
 Three heterozygous SCA3 knock-in brains immunohistochemically stained for 
ATXN3 were systematically scored for diffuse nuclear staining, intranuclear inclusions, 
and extranuclear inclusions. Staining patterns indistinguishable from wild-type mice were 
scored as -. The presence of diffuse nuclear staining was represented by + or ++. 
Frequency of solitary intranuclear inclusions or extranuclear inclusions were scored by +, 
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++, or +++. Intranuclear versus extranuclear inclusions were further confirmed by co-
immunofluorescent staining with nuclear DAPI. Examples of scoring diffuse nuclear 
staining and intranuclear inclusions are shown in Figure 3.6 (Chapter 3).   
2.6 Motor behavior testing and fear conditioning 
The examiner was blinded to the genotype in all behavioral experiments. Motor 
function was assessed on SCA3 knock-in mice using tests as previously reported (145), 
including performances on accelerating rotarod, balance beam, and locomotor activity in 
an open field chamber for 30 min. In chapter 3, I tested Q82/Q6 and wild-type mice 
ranging from 47 to 57 weeks of age. Motor performance on day 4 and open field activity 
were analyzed using a Student t-test with a Bonferroni post-hoc correction for three 
comparisons. In chapter 4, I tested wild-type, Q82/Q6, and Q82V/Q6 mice ranging from 
53 to 61 weeks of age. I analyzed four day accelerating rotarod data by a two-way 
ANOVA, and I analyzed day 4 balance beam performance and open field locomotor 
activity by a one-way ANOVA with a Newman-Keuls multiple comparisons test.   
In chapter 3, fear conditioning was performed on Q82/Q6 mice and wild-type 
littermates ranging from 52 to 60 weeks of age using the protocol previously described 
for single-day experiments (161). These experiments were performed in collaboration 
with Dr. Geoffrey Murphy (University of Michigan) These mice were then sacrificed and 
examined for aggregates in the hippocampus and amygdala.  
2.7  RNA extraction, RNA sequencing, quantitative PCR, and 3’ RACE 
RNA was extracted from pons or half of the hindbrain of mice using TRIzol ® 
(Life Technologies) and further purified using the RNeasy kit with on-column DNase I 
digestion (Qiagen). Purified RNA was submitted to the University of Michigan 
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Bioinformatics Core for library generation and Illumina HiSeQ RNA-sequencing. The 
RNA-seq data reported in chapter 3 utilized a NuGen library with 50x50bp sequencing, 
while chapter 4 used a TruSeq library with 100x100bp sequencing. Each sample was 
sequenced on at least one lane. The sequencing reads for each mouse were aligned using 
TopHat and the output was sorted and indexed using SAMtools to generate a BAM file. 
We visualized Atxn3 transcript reads in each BAM file using Integrative Genomics 
Viewer (162, 163).  Fragments per kilobase of exon per million fragments mapped 
(FPKMs) reported for the full-length Atxn3 transcript (accession NM_029705)were 
created by CuffLinks. We used a locally developed R script, in conjunction with 
CummeRbund, to output a table of all expression values (raw, externally normalized, and 
FPKM).   
Chapter 4 presents altered transcripts from RNA-seq in a heat map format. To 
generate the heat map, the calculated Cuffdiff values were normalized to wild-type to 
determine relative fold-change for differentially expressed (DE) transcripts. Differentially 
expressed (DE) transcripts were identified through DEseq (DESeq.padj 0.1 cutoff, fold-
change 0.8 – 1.2). For the ~150 DE transcripts of YAC-84Q mice, fold-change values 
relative to wild-type were generated for different genotypes and inputted into 
MultiExperiment Viewer to generate a heat map (http://www.tm4.org/mev.html).  
Gene enrichment analysis was done through ToppGene (164). Cell-type 
expression was determined from publically-available RNA-seq data on mouse cerebral 
cortex (http://web.stanford.edu/group/barres_lab/brain_rnaseq.html) (165). 
For quantitative RT-PCR (qRT-PCR), 1g of RNA was reverse-transcribed using 
iScript™. 0.5 l was used with the SYBR® Green Master Mix and each reaction was 
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performed in duplicate. qRT-PCR was performed on the BioRad iCycler with MyIQ 
single color real-time PCR detection system  module with the following parameters: 
95°C at 3min, (95°C 10 sec, 55°C 30sec) x 40, 95°C 1 min, 55°C 1 min. The fold-change 
in transcript levels was calculated using the Ct method (166). Gapdh and ACTB were 
used as controls for SCA3 knock-in mice and patient fibroblasts, respectively. For 
examining relative levels of ATXN3 transcripts in SCA3 YAC mice, human TRIP11 was 
used, since the YAC-15Q and YAC-84Q mice contain different copy numbers of the 
same integrated YAC construct, which also expresses the TRIP11 gene. 3’RACE was 
performed on 2g of RNA from an Q82/Q6 mouse hindbrain per the manufacturer’s 
instructions (Life Technologies). 3’ RACE products were run on an agarose gel and the 
300 bp band of interest was extracted, TA-cloned (Life Technologies), and sequenced. 
The primers used for RT-PCR and 3’RACE are listed below. 
In chapter 3, DNase I-treated RNA samples from six SCA3 fibroblast lines and 
one non-disease control fibroblast line were kindly provided by Dr. Guangbin Xia and 
Dr. Tetsuo Ashizawa (University of Florida, Gainesville, FL, USA). RNA was also 
isolated from three additional non-disease fibroblast lines that were graciously provided 
by Crystal Pacut and Dr. Eva Feldman (University of Michigan, Ann Arbor, MI, USA).  
2.8 Primers  
Amplicon Forward primer (5’ to 3’) Reverse primer (5’ to 3’) Exp. 
Atxn3 intron 9 
– exon 10 
TTCACGTTTGAATGTTTCAGG ATATGAAAGGGGTCCAGGTCG Genotype 
Atxn3 exon 10 -  
intron 10 
GGACGTAGGAGCGACCAAG CGAGGATCTTGGGTATCGAGT qRT-PCR  
Atxn3 exon 10 TAGACCGACCTGGACCCCTT CTTGGTCGCTCCTACGTCC qRT-PCR 
ATXN3 exon 






ATXN3 exon 10 GACCTATCAGGACAGAGTTCAC CTAGATCACTCCCAAGTGCTC
C 
qRT-PCR 
Atxn3 exon 10- GAGCACTTGGGAGTGATCTAG ATCACATGGAGCTCGTATGTC qRT-PCR 
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exon 11   AG 





ATXN3 exon 1 













Atxn3 intron 10  TACTCGATACCCAAGATCCTCGTC Provided by 3’ RACE kit 
(Invitrogen) 
3’RACE 
Gapdh CTTTGTCAAGCTCATTTCCTG TCTTGCTCAGTGTCCTTG qRT-PCR 
TRIP11 GCCAGTCTCTGGGTCAAGTC AATTCTGCTTCCACTTCCTCCG qRT-PCR 
ACTB CGTCCACACCCGCCG CCACCATCACGCCCTGG qRT-PCR 




Smoc1 TTCAGGAAGAAAAGATGATGGCT ATCCATAAGGTGGGGGCTGT qRT-PCR 
Agt TGTCTAGGTTGGCGCTGAAG GATGTATACGCGGTCCCCAG qRT-PCR 
Dao GTCAACACAGCCCAGAGAGT CCAATGACTCCTGCTCCGAT qRT-PCR 
Il33 AGGGAGAAATCACGGCAGAA TATTTTGCAAGGCGGGACCA qRT-PCR 
 
2.9 Plasmids and cell culture experiments   
Non-expanded mouse Atxn3 cDNA was amplified by PCR from a wild-type 
mouse, and different expanded mouse Atxn3 cDNA were amplified from SCA3 knock-in 
mice. Amplified PCR products were extracted from a 1% agarose gel and TA-cloned into 
a pcR2.1 plasmid (Invitrogen) and subcloned into pcDNA 3.1 between BamHI and NotI 
sites. All constructs were ligated with T4 DNA ligase (New England BioLabs) and 
transformed into TOP10 cells (Invitrogen). The final constructs included those expressing 
nonexpanded mouse ATXN3 (Wild-type), full-length Q74 mouse ATXN3 (Q74-FL), and 
intron 10-containing Q71 mouse ATXN3 (Q71-int10). Plasmids were isolated with the 
QIAprep Spin Miniprep Kit (QIAGEN) and confirmed by sequencing before transfecting 
into cells.  
PC12 cells were maintained at 37°C, 5% CO2 in DMEM, 10% FBS, 1% 
penicillin/streptomycin/glutamine. Cells were transiently transfected with 500ng DNA in 
100 L OptiMem, using Lipofectamine PLUS Reagents, according to the manufacturer’s 
protocol. Coverslips were coated with polyD lysine (Millipore) and incubated for 24 
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hours at 37°C. Cells were plated on polyD lysine-coated coverslips and transfected 24 
hours later. 72 hours after transfection, cells were fixed in 4% paraformaldehyde/PBS and 
immunostained for ATXN3 (1H9, 1:1000).  To quantify ATXN3 puncta, several fields 
were randomly selected using a 60x objective on an Olympus IX71 inverted microscope 
per transfected coverslip. The number of inclusions among nine fields was averaged for 
three separate experiments and graphed for each construct.  
2.10 Statistical analysis    
All statistics were performed in Graphpad Prism. Western blot and qRT-PCR 
experiments comparing two conditions were analyzed by a Student’s t-test.  For studies 
comparing three conditions, I performed a one-way ANOVA with the Newman-Keuls 
multiple comparisons test. P-values less than 0.05 were considered statistically 
















Figure 2.1 Retained sequences in the mutant Atxn3 locus of SCA3 knock-in mice. 
Sequencing of a SCA3 knock-in mouse across the FRT site showed successful removal 
of the neomycin cassette from the SCA3 knock-in mouse, and the remaining sequences 
from the targeting vector (bold and in brackets) approximately 350 bp upstream of exon 
10. This 110 bp sequence includes the engineered SalI and KpnI sites at the ends, a single 





A knock-in mouse model of Spinocerebellar Ataxia type 3 
exhibits prominent aggregate pathology and aberrant splicing 
of the disease gene transcript 
3.1 Abstract 
Polyglutamine diseases, including Spinocerebellar ataxia type 3 (SCA3), are 
caused by CAG repeat expansions that encode abnormally long glutamine repeats in the 
respective disease proteins. While the mechanisms underlying neurodegeneration remain 
uncertain, evidence supports a proteotoxic role for mutant proteins dictated in part by the 
specific genetic and protein contexts. To further define pathogenic mechanisms in SCA3, 
we generated a mouse model in which a CAG expansion of 82 repeats was inserted into 
the murine locus by homologous recombination. SCA3 knock-in mice exhibit region-
specific aggregate pathology marked by intranuclear accumulation of the mutant ATXN3 
protein, abundant nuclear inclusions and, in select brain regions, extranuclear aggregates 
localized to neuritic processes. Knock-in mice also display altered splicing of the disease 
gene, promoting expression of an alternative isoform in which the intron immediately 
downstream of the CAG repeat is retained. In an independent mouse model expressing 
the full human ATXN3 disease gene, expression of this alternatively spliced transcript is 
also enhanced. These results, together with recent 
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findings in other polyglutamine diseases, suggest that CAG repeat expansions can 
promote aberrant splicing to produce potentially more aggregate-prone isoforms of the 
disease proteins. This first report of a SCA3 knock-in mouse expands the repertoire of 
existing models of SCA3, and underscores the potential contribution of alternative 
splicing to disease pathogenesis in SCA3 and other polyglutamine disorders. The work of 
this chapter has been published in Ramani et al (151). 
3.2 Introduction 
Spinocerebellar ataxia type 3 (SCA3), also known as Machado-Joseph disease, is 
the most common dominantly inherited ataxia and one of at least nine neurodegenerative 
diseases caused by polyglutamine-encoding CAG repeat expansions (167). In SCA3, this 
expansion occurs in the ATXN3 gene which encodes the deubiquitinase ataxin-3 
(ATXN3) (111). Like other polyglutamine diseases, SCA3 is a disabling and ultimately 
fatal disorder characterized by selective degeneration in specific brain regions and age-
dependent intraneuronal accumulation and aggregation of the mutant protein (2, 6). 
While neuronal inclusions formed by the disease protein may not be directly toxic in 
polyglutamine disease (37, 38), evidence supports the view that inclusions are a marker 
for accumulated, misfolded polyglutamine protein that is proteotoxic and contributes to 
neuronal dysfunction and cell loss in disease (16, 19–21, 168). Unfortunately, despite 
recent advances in understanding polyglutamine diseases, no preventive treatments are 
available for any.  
Animal models have been instrumental in providing insight into polyglutamine 
disease pathogenesis and suggesting routes to potential therapy.  Existing animal models 
of SCA3 have advanced the field in many ways, but all of them overexpress mutant 
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ATXN3 above physiological concentrations (110). While overexpression models are 
particularly good at recapitulating robust aggregation pathology and behavioral 
abnormalities, they may mask early molecular changes important to pathogenesis. 
Moreover, models overexpressing a single isoform of ATXN3 from cDNA do not permit 
investigations of the potential disease contribution of splicing changes in the mutant 
transcript. In contrast, “knock-in” models in which the CAG repeat expansion is inserted 
precisely into the endogenous murine locus  have proved useful in understanding various 
aspects of polyglutamine disease (48, 68, 80, 81, 85–87, 142, 147, 153) including altered 
splicing of mutant transcripts (85, 86). For example, Sathasivam et al. recently discovered 
that the CAG expansion in Huntington’s disease knock-in mice promotes aberrant 
splicing of the Htt transcript and the production of a truncated amino-terminal fragment 
of the disease protein, Htt (86). Genetically precise knock-in mouse models express the 
mutant protein from the endogenous promoter in the proper genomic context, including 
all regulatory elements that influence mutant gene expression.  
Knock-in mouse models have been generated for most polyglutamine diseases, 
but none exists for SCA3. Here, we report the first SCA3 knock-in mouse model, 
generated by replacing the endogenous murine CAG repeat with an 82 repeat CAG 
expansion. Expressing physiological levels of mutant ATXN3, the SCA3 knock-in mice 
exhibit robust ATXN3 accumulation both in regions known to be affected in human 
disease (e.g. brainstem and cerebellum) and in regions not previously described (e.g. 
hippocampus). SCA3 knock-in mice also display altered splicing of the mutant Atxn3 
transcript that results in the formation of a previously described alternative ATXN3 
transcript in human disease (98). We further show that CAG expansion results in similar 
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altered splicing in another mouse model expressing the full length human ATXN3 
disease gene. In summary, the SCA3 knock-in mouse model reported here recapitulates 
several important molecular features of disease and should facilitate the study of early 
pathogenic events in this polyglutamine disease.  
3.3 Results  
3.3.1 Generation of the SCA3 knock-in mouse model and mutant ATXN3 expression 
SCA3 is caused by CAG expansions ranging from  ~60 to 87 repeats in the 
ATXN3 gene (169). We inserted a CAG repeat expansion at the upper end of this disease 
range into the endogenous murine Atxn3 locus on a C57BL/6 background (Figure 3.1A). 
By homologous recombination we replaced the endogenous murine sequence 
CAA(CAG)5 with (CAG)2(CAAAAG)(CAG)82 which encodes 85 glutamines 
interrupted by a lysine at the fourth residue (i.e. Q3KQ82), replicating the polyglutamine 
stretch found in human mutant ATXN3 (98).  PCR across the endogenous CAG repeat 
confirmed successful insertion of the pathogenic expansion in heterozygous (Q82/Q6) 
and homozygous (Q82/Q82) SCA3 knock-in mice (Figure 3.1B). Sequencing of the 
intronic region upstream of the repeat expansion confirmed the removal of the neomycin 
cassette and the presence of the remaining FRT sequence (Figure 3.2), and sequencing of 
exon 10, all of intron 10 and exon 11 did not reveal any differences compared to wild-
type mice other than the expansion (data not shown).  CAG repeat length sizing in 
offspring of heterozygous Q82/Q6 mice revealed a modest tendency toward CAG repeat 
contraction upon maternal transmission of the mutant allele and stabilization or mild 
expansion upon paternal transmission (Figure 3.1C). Similar intergenerational repeat 
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instability has been reported in other polyglutamine disease mouse models, including a 
transgenic mouse model of SCA3 (40, 80, 81, 170).  
 Mutant ATXN3 is expressed widely throughout the SCA3 knock-in mouse, 
including in the brain, heart, liver, muscle and spleen (155). Western blot analysis of 
hindbrain lysates from one-year-old Q82/Q6 mice confirmed mutant ATXN3 expression 
in the brain, as well as aggregated ATXN3 protein in the stacking gel (Figure 3.1D). 
Electrophoresis of brain lysates from knock-in mice on low percentage (3%) SDS-PAGE 
further illustrated a range of high molecular weight aggregate species (Figure 3.1E). 
Analysis of hindbrain lysates from homozygous Q82/Q82 knock-in mice revealed 
exclusively mutant (expanded) ATXN3 expression with a corresponding loss of wild-
type ATXN3, confirming that mutant ATXN3 is expressed from the endogenous allele 
(Figure 3.1F). The increased high molecular weight aggregate species are consistent with 
detergent-resistant aggregates previously reported in a SCA3 transgenic mouse model 
(16, 171). In heterozygous mice, the decreased intensity of mutant ATXN3 monomer 
compared to wild-type ATXN3 monomer is also consistent with the aggregation 
propensity of expanded polyglutamine proteins (149).  
3.3.2 Neuropathological and behavioral characterization of the SCA3 knock-in 
mouse 
To begin defining neuropathological changes in SCA3 knock-in mice, we 
immunostained for ATXN3 in SCA3 knock-in brain. Compared to other polyglutamine 
disease knock-in mouse models in which CAG expansions within the human disease 
range often elicit relatively modest neuropathological findings (136, 139, 140, 150),  
SCA3 knock-in mice display comparatively robust aggregate pathology. In heterozygous 
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mice, enhanced intranuclear staining for ATXN3 is present by 10 weeks in several 
neuronal populations, including the deep cerebellar nuclei (DCN) (Figure 3.2A), and is 
often accompanied by small intranuclear puncta. We do not reliably detect 
immunohistochemical changes in Q82/Q6 mice that are less than ~ six weeks of age. One 
year old heterozygous Q82/Q6 knock-in mice display more prominent intranuclear 
puncta, as well as more frequent solitary inclusions that are characteristic of the human 
disease (Figure 3.2B). Neuronal inclusions in the SCA3 knock-in mice often co-localize 
with p62, an ubiquitin binding protein implicated in autophagy and previously reported  
to localize to intranuclear inclusions in SCA3 disease brains (172–174) (Figure 3.2D, 
Figure 3.3).  
SCA3 knock-in mice display striking regional differences in mutant ATXN3 
deposition. Table 3.1 (with Figure 3.6) qualitatively report the intensity of diffuse nuclear 
staining and frequency of intranuclear inclusions in various brain regions in one-year-old 
heterozygous mice (n=4). Neurons of the hindbrain, including the DCN and several brain 
stem nuclei, which are known to be vulnerable targets in the human disease, show strong 
diffuse nuclear staining that is often accompanied by multiple intranuclear puncta and 
less frequently by distinct solitary large inclusions. In contrast, neurons of the forebrain, 
including the hippocampus, cortex, and striatum, have moderately increased diffuse 
nuclear staining with frequent solitary intranuclear inclusions. Despite widespread 
aberrant accumulation of mutant ATXN3, including in the hindbrain, one year old 
Q82/Q6 mice (n=9) performed equally well as age-matched wild-type mice (n=10) on 
various motor tasks (Figure 3.2E). Examination of cresyl-violet-stained brains of one-
year-old Q82/Q6 mice (n=3) did not reveal obvious degenerative changes in any brain 
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regions. For example, a close examination of the DCN, a region known to be consistently 
affected in SCA3, did not suggest neuronal loss at one year of age (Figure 3.4).  
We also observed striking extranuclear neuronal aggregates in select brain 
regions, summarized in Table 3.1. In one-year-old knock-in mice, for example, ubiquitin-
positive extranuclear inclusions are especially abundant in the stratum radiatum of the 
hippocampus, which also shows frequent ubiquitin-positive intranuclear inclusions in 
pyramidal neurons (Figure 3.5A and B). Extranuclear inclusions are also present in the 
subiculum, central amygdala, and bed nucleus of the stria terminalis. Extranuclear 
inclusions in the hippocampus often co-localize with anti-MAP2 and SMI32 antibodies, 
suggesting that they reside in dendrites (Figure 3.5C). At three months of age they are 
detected as small puncta in the hippocampal neuropil and grow over time into large, often 
irregular structures by one year of age. In a two-year-old Q82/Q6 mouse, many of these 
large inclusions co-localized with reticulon-3 (RTN3), a potential marker for dystrophic 
neurites (175, 176) (Figure 3.5D). We also examined soluble lysates of SCA3 knock-in 
mouse hindbrain and hippocampus by western blot, but did not detect regional 
differences in levels of soluble, monomeric mutant ATXN3 or of high molecular weight, 
aggregated ATXN3 species (Figure 3.7).  
The presence of robust hippocampal pathology prompted us to perform a test of 
fear conditioning to shock, which broadly assesses hippocampal- and amygdala-
dependent memory consolidation (177).  We did not observe significant differences in 
freezing to context or tone in one-year-old Q82/Q6 mice (n=9) compared to wild-type 
littermates (n=9) (Figure 3.5E). All SCA3 knock-in mice tested in this experiment were 
later confirmed to contain extensive extranuclear aggregates in the hippocampus and 
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central amygdala nucleus (not shown). In summary, SCA3 knock-in mice exhibit robust 
aggregate pathology throughout the brain upon physiological expression of 
polyglutamine-expanded ATXN3 and thus are well suited to explore the early molecular 
changes contributing to disease pathogenesis.  
3.3.3 Alternative processing of mutant ataxin-3 transcript in SCA3 
Many polyglutamine diseases and mouse models of disease are associated with 
transcriptional changes that may contribute to disease pathogenesis (53, 67). To identify 
early transcriptional and splicing changes in SCA3 knock-in mice, including potential 
alterations in the Atxn3 transcript itself, we performed RNA-sequencing on a vulnerable 
brain region in SCA3, the pons, from 6 month old wild-type (n=7) and homozygous 
SCA3 knock-in mice (n=7). A full analysis of transcriptional changes will be reported 
later. In this study, we focus on intriguing differences noted in expression of the Atxn3 
transcript itself.  
The human ATXN3 and murine Atxn3 genes both contain 11 exons, with the CAG 
repeat residing in exon 10. At least two major ATXN3 transcript variants are expressed in 
humans: a full length, 11 exon ATXN3 (ATXN3-11e) transcript that contains the entire 
ATXN3 protein coding sequence; and a 10 exon (ATXN3-10e) transcript that retains 
intron 10 and lacks exon 11 (98, 178). The ATXN3-11e transcript (RefSeq NM_004993) 
encodes the ATXN3 isoform MJD1c (107, 178), whereas the ATXN3-10e transcript 
(RefSeq S75313), initially identified  by Kawaguchi et al. when they reported the disease 
mutation in SCA3 (98), encodes isoform MJD1a or MJD1b depending on a 
polymorphism that alters the location of the stop codon. In this study, we refer to these 
transcripts and corresponding protein isoforms by the number of exons (10e and 11e). We 
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previously reported that ATXN3-11e is normally the most abundantly expressed isoform 
in the brain and that the less abundant ATXN3-10e isoform is more unstable and 
aggregation-prone in cell models (109). The unstable, aggregation-prone nature of 
ATXN3-10e may reflect the presence of a carboxy-terminal hydrophobic domain that is 
encoded by read-through into the intron downstream of exon 10. This domain is absent 
from ATXN3-11e, which instead ends with a domain containing an Ubiquitin Interacting 
Motif (UIM).  
Unexpectedly, comparison of aligned sequencing reads revealed markedly 
elevated reads into intron 10 of Atxn3 in SCA3 knock-in mice, whereas few intronic 
reads were present in wild-type mice  (Figure 3.8B). These increased reads continue ~300 
bp into intron 10, ending near a putative polyadenylation site (ATTAAA) and suggesting 
that the transcript could terminate and become polyadenylated at this site.  Indeed, 3’ 
RACE on Q82/Q6 mouse RNA to the beginning of intron 10 revealed a ~300 bp band, 
which sequencing confirmed is a putative Atxn3-10e transcript polyadenylated at this 
predicted polyA site in intron 10 (Figure 3.8C). Importantly, despite the increased 
expression of the Atxn3-10e transcript, SCA3 knock-in mice still express the Atxn3-11e 
variant. RNA-sequencing reads containing exon 11 and the established Atxn3 3’ UTR 
appear to be equally present in wild-type and SCA3 knock-in mice (Figure 3.8D):  
normalized levels (FPKMs) of predicted full-length Atxn3-11e transcript (accession 
NM_029705.3) did not differ significantly between wild-type and mutant mice (Figure 
3.8E). Except for the differences noted at the exon 10/intron 10 junction, we did not 
observe striking or consistent changes in reads across the entire Atxn3 gene (Figure 3.9).   
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To further quantify Atxn3-10e transcript levels in SCA3 knock-in mice, we 
performed quantitative PCR on reverse-transcribed RNA (qRT-PCR) from brain using 
primers against the exon 10/intron 10 junction. We also separately performed qRT-PCR 
using primers that amplify only exon 10 to estimate total (exon 10-containing) Atxn3 
transcript levels (Figure 3.10A). Atxn3-10e transcript levels proved to be markedly 
increased in 3-month-old Q82/Q6 mice compared to age-matched wild-type mice, 
whereas total exon 10-containing transcripts (i.e., 10e and 11e variants combined) 
showed a more modest upregulation in knock-in mice (Figure 3.10B). The basis for the 
upregulation of total Atxn3 transcript in SCA3 knock-in mice is not clear but may reflect 
differences in the regulation of Atxn3-10e and Atxn3-11e transcripts since they utilize 
different 3’UTRs. We also cannot exclude the possibility that the manipulation of the 
endogenous murine Atxn3 gene, including the presence of the FRT site, alters its 
expression. 
To determine whether the increased levels of this alternative isoform reflect the 
presence of a CAG expansion, we investigated an independent SCA3 mouse model: YAC 
transgenic mice that express the full human ATXN3 gene with either a normal repeat 
(YAC-15Q) or an expanded repeat (YAC-84Q) (159). Employing qRT-PCR with primers 
against ATXN3 (Figure 3.10A), we observed significantly elevated ATXN3-10e transcript 
levels in the pons of ~5 month old YAC-84Q mice compared to age-matched YAC-15Q 
mice (Figure 3.10C).   These results suggest that CAG repeat expansions are associated 
with increased production of the ATXN3-10e transcript. To further explore this possibility 
we analyzed ATXN3 transcripts in fibroblasts derived from SCA3 patients (n=6) or non-
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disease controls (n=4) (Figure 3.10D). By qRT-PCR, however, ATXN3-10e transcript 
expression levels did not differ significantly between disease and control fibroblasts. 
To verify that the ATXN3/Atxn3-10e transcripts observed above contain the rest of 
the amino-terminal protein coding sequence, we performed non-quantitative PCR using 
primers to amplify from exon 1 to intron 10 (Figure 3.10A) on the same reverse-
transcribed RNA preparations described above. We note that this PCR is non-quantitative 
because large GC-rich repeats (i.e. expanded CAG repeats) are poorly amplified by the 
polymerase. PCR amplified a single band from Q82/Q6 mice but none from wild-type 
mice (Figure 3.10E). Sequencing confirmed this band to be Atxn3-10e cDNA containing 
the first 10 exons followed by read through into intron 10. Thus, SCA3 knock-in mice 
express the full Atxn3-10e transcript with a CAG repeat expansion, analogous to the 
ATXN3-10e transcript in humans. Importantly, non-quantitative PCR showed that the 
complete ATXN3-10e transcript is also expressed in YAC mice expressing normal or 
expanded ATXN3, in 3 of 4 control fibroblast lines, and in all SCA3 disease fibroblast 
lines, including from the non-expanded allele (Figure 3.10F, G). The one control line that 
did not produce a detectable PCR signal (lane 3) showed reduced levels of total RNA by 
quantitative PCR, which may prevent detection of the less abundant ATXN3-10e 
transcript by PCR. This sample demonstrated proportionally lower levels of ATXN3-10e, 
total ATXN3, and ACTB transcripts. PCR amplification from ATXN3 exon 7 to 11 
demonstrated that ATXN3-11e is present in this and all other fibroblast lines (Figure 
3.10G).  
The expression of the ATXN3-10e transcript even in normal human fibroblasts 
suggests that the relatively larger CAG repeat length of the normal human ATXN3 gene 
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(20-42 repeats) may support the production of the ATXN3-10e transcript. In contrast, 
wild-type mice, which have only 5 CAG repeats, show nearly undetectable levels of 
Atxn3-10e transcript, leading to a dramatically higher fold-change in the SCA3 knock-in 
mice. Tissue-specific differences could further mask CAG repeat-dependent splicing 
changes in SCA3 fibroblasts.  
3.4 Discussion 
The SCA3 knock-in mouse reported here expresses mutant ATXN3 with an 
expansion in the human disease range and exhibits robust accumulation and aggregation 
of mutant ATXN3 in the brain, detected biochemically and immunohistochemically. In 
addition to replicating the intranuclear accumulation and inclusions described in human 
disease tissue, SCA3 knock-in mice also develop extensive neuritic aggregates in select 
brain regions, most notably the hippocampus. SCA3 knock-in mice harboring a CAG 
expansion also display marked retention of intron 10 in Atxn3 transcripts, a finding we 
confirmed in an independent mouse model of SCA3 expressing the full human disease 
gene. Based on these results, this SCA3 knock-in mouse model represents an important 
addition to existing models of disease that should prove particularly useful for the study 
of early molecular changes including mutant protein aggregation and alternative splicing. 
Despite only modest expression of the mutant protein from the endogenous locus, 
SCA3 knock-in mice manifest relatively early signs of ATXN3 accumulation in the 
brain, including increased concentration in neuronal nuclei and the formation of 
intranuclear puncta and larger inclusions. ATXN3 accumulation is noted especially in 
neurons of the hindbrain known to be affected in SCA3, such as DCN and brainstem 
neurons (105). Nuclear localization of the mutant protein is believed to contribute to 
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disease pathogenesis in various polyglutamine diseases including SCA3 (50–52), and this 
new model could facilitate the study of factors acting early to regulate nuclear trafficking 
and handling of mutant ATXN3. The knock-in mouse model also should assist the 
dissection of posttranslational modifications occurring to mutant ATXN3 in vivo 
including proteolytic cleavage, phosphorylation, and ubiquitination, as well as their 
impact on disease protein behavior.  
SCA3 knock-in mice also develop striking neuritic inclusions, particularly in the 
synapse-rich stratum radiatum of the hippocampus. The mechanisms driving the 
formation of these aggregates remain unclear. Deficits in trafficking and/or clearance of 
misfolding proteins in the distal reaches of pyramidal neurons may precipitate the 
formation of inclusions in subcellular compartments far removed from clearance 
mechanisms concentrated in the cell soma. A recent study showed that removing p62 in 
HD mouse models led to increased MAP2-positive HTT aggregates in the stratum 
radiatum that look strikingly similar to the ones shown here (179). Alternatively, neuritic 
aggregates could arise as a consequence of neuronal activity, which has been proposed to 
promote cleavage and aggregation of mutant ATXN3 at synapses (180). While the 
hippocampus is not considered a major disease target in SCA3, the study of the 
anatomically layered and easily accessible hippocampus could provide unique 
opportunities to study misfolded protein handling in axons and dendrites. Furthermore, an 
increasing number of studies report cognitive dysfunction in SCA3, which may reflect 
forebrain pathology (102–104). Axonal and cytoplasmic inclusions have been reported in 
SCA3 (106), but the extent to which they affect neuronal function is unknown. Future 
studies on the formation of extranuclear aggregates in SCA3 knock-in hippocampus may 
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provide insight into the handling of misfolded protein in neurites. Our findings also 
underscore the need for further pathological characterization of SCA3 disease tissue, 
including of the cortex and hippocampus.  
The absence of behavioral deficits and overt neuropathological changes in 
heterozygous SCA3 knock-in mice despite prominent disease protein aggregation is 
perhaps not surprising given the low-level, physiological expression of the Atxn3 disease 
gene. Knock-in mice with CAG repeat lengths in the human disease range, as in this 
study, often display mild or no behavioral deficits (80, 138, 140, 150). For example, 
SCA1 78Q knock-in mice manifested mild abnormalities only when homozygous for the 
mutant allele (80). It will be important to look for motor deficits and molecular markers 
of degenerative change in aged homozygous SCA3 knock-in mice, which we are in the 
process of generating. The absence of an overt behavioral phenotype in this and many 
other age-related neurodegenerative disease models highlights the point that such models 
are best at providing insight into pathogenic mechanisms that precede neuronal loss.  
Intriguingly, SCA3 knock-in mice exhibit altered splicing of the mutant Atxn3 
transcript, mirroring the formation of a known alternative ATXN3 transcript in humans. 
Increased retention of intron 10 in mutant Atxn3 transcripts parallels the findings of 
Sathasivam and colleagues, who observed the retention of intron 1 in mutant Htt 
transcripts following the CAG repeat-containing exon 1 in a knock-in mouse model of 
HD and suggested that differential binding of splicing factors mediates aberrant splicing 
of the mutant transcript (86, 181). Alternatively, differences in the kinetics of 
transcription through an expanded repeat may shift polyadenylation site usage (182–184). 
Shared mechanisms across polyglutamine diseases may dictate aberrant splicing of CAG 
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repeat-containing transcripts, potentially producing more toxic isoforms of disease 
proteins in several polyglutamine disorders. We previously reported that even a non-
expanded form of the  ATXN3-10e variant is more aggregate-prone and less stable than 
the full-length isoform, suggesting that the higher hydrophobicity of the carboxy-
terminus encoded by translational read-through into intron 10 increases overall 
aggregation propensity (109). If identified, factors that shift splicing to favor production 
of the full-length (i.e. 11e) ATXN3 isoform might represent targets through which to 
lessen mutant protein aggregation. The SCA3 knock-in mouse should facilitate studies to 
identify such factors.  
Unfortunately, the high degree of similarity between the 10e and 11e ATXN3 
isoforms raises challenges in distinguishing the two encoded proteins. We previously 
showed that these two isoforms have slightly different electrophoretic properties, but 
were unable to distinguish the ATXN3-10e isoform from ATXN3-11e isoform in 
ATXN3Q84-YAC mice (109). In addition, decreased solubility of the ATXN3-10e 
isoform may impede its detection by conventional biochemical methods. While both the 
ATXN3-11e and ATXN3-10e transcripts are presumably made in the human brain, their 
relative abundance in the SCA3 disease brain is not known. Future studies will be needed 
to quantify the expression of alternative ATXN3 transcripts and ATXN3 protein isoforms 
in human brain in order to determine their relative contribution to disease pathogenesis. 
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Figure 3.1 Generation of a SCA3 knock-in mouse expressing mutant ATXN3 (Q82). 
(A) Schematic of the generation of the SCA3 knock-in mouse in which the endogenous 
murine (CAA)(CAG)5 was replaced with a human CAG expanded sequence, 
(CAG)2(CAAAAG)(CAG)82, by homologous recombination. The neomycin (neo) 
selection cassette, flanked by FRT sites, was removed by FLPe recombination. These 
steps were performed by Dr. Ginny Harris. (B) PCR across the CAG repeat shows the 
expanded repeat in heterozygous (Q82/Q6) and homozygous (Q82/Q82) SCA3 knock-in 
mice. (C) SCA3 knock-in mice show modest intergenerational repeat length instability 
with a tendency for CAG repeat contraction upon maternal transmission. (D) Western 
blotting shows expression of mutant ATXN3 accompanied by increased aggregates in the 
stacking gel in 1-year-old Q82/Q6 hindbrain lysates. (E) Electrophoresis of lysates from 
(D) on 3% SDS-PAGE further illustrates high molecular weight aggregates. (F) ~30-
week-old homozygous Q82/Q82 mice express only mutant ATXN3 with aggregates in 





Figure 3.2 Mutant ATXN3 accumulation in the SCA3 knock-in mouse brain. (A) 
Immunohistochemical staining (IHC) for ATXN3 shows nuclear accumulation in the 
DCN of a 10-week-old Q82/Q6 mouse. Scale bar = 20m, inset scale bar = 2m. (B) 
IHC of one-year-old Q82/Q6 mice shows increased diffuse nuclear staining and 
intranuclear puncta/inclusions in several brain regions, including the brain stem (medulla 
shown), deep cerebellar nuclei (DCN), and the hippocampus (CA1 region is shown). 
Higher magnification insets show puncta and inclusions in nuclei. (C) Intranuclear 
accumulation of ATXN3 (DCN shown) is accelerated in a ~7-month-old homozygous 
Q82/Q82 mouse compared to a heterozygous littermate. Scale bar = 20 m (D) ATXN3-
immunoreactive (green) intranuclear puncta and inclusions in brainstem neurons from 
SCA3 knock-in mice frequently co-stain with p62 (red), whereas p62 is predominantly 
cytoplasmic in wild-type neurons. The nuclear border is outlined by a dashed line.  Scale 
bar = 10m. (E) Performance of one-year-old Q82/Q6 (Q82/Q6) mice (n=9) did not 
differ from age-matched wild-type (WT) mice (n=10) on motor behavior tasks, including 
from left to right, 5mm balance beam, accelerating rotarod, and open field exploration. 




Figure 3.3 ATXN3 and p62 co-immunostaining in a heterozygous Q82/Q6 mice. 
Epifluorescent images showing that Atxn3 inclusions in a one-year-old Q82/Q6 mouse 
are immunoreactive for p62 in brainstem and hippocampal pyramidal neurons that 
coexpress NeuN. Scale bar = 10 m 
 
 
Figure 3.4 Cresyl-violet staining of Q82/Q6 brain. One-year-old Q82/Q6 mice do not 
show obvious degenerative changes in the DCN by cresyl violet staining. Left panels, 






Figure 3.5 Extranuclear inclusions in the hippocampus of SCA3 knock-in mice. (A) 
Large extranuclear inclusions are concentrated in stratum radiatum (SR) of the 
hippocampus one-year-old Q82/Q82 mice. Right, immunofluorescence of a different 
Q82/Q82 mouse showing that inclusions do not colocalize with nuclear DAPI. Bottom 
panel shows magnified view of inclusions. (B) Hippocampal aggregates are often 
ubiquitin-positive, including both intranuclear inclusions in CA1 pyramidal neurons (left) 
and extranuclear inclusions in the stratum radiatum (right). (C) Extranuclear inclusions 
show overlap with dendritic markers MAP2 and SMI32. (D) Large Atxn3 extranuclear 
inclusions in the stratum radiatum of a two-year-old Q82/Q6 mouse stain for reticulon-3 
(RTN3), a marker for dystrophic neurites. (E) One-year-old Q82/Q6 mice (n=9) did not 
differ from wild-type mice (n=9) in tests of fear conditioning, including freezing to 
context (left) and tone (right). Scale bars in (A) top and bottom panels are 50m and 
10m, respectively. Scale bars in (B-D) are 10m.  
59 
 
Region Diffuse nuclear staining Intranuclear inclusions Extranuclear inclusions 
Purkinje cells - + - 
Granular cells + - - 
Deep cerebellar nuclei ++ ++ - 
Medulla ++ ++ + 
Pons ++ ++ + 
Substantia nigra + + - 
Red nucleus ++ ++ - 
Spinal cord ++ ++ + 
Striatum + +++ + 
Hippocampus + +++ +++ 
Amygdala + - ++ 
Cortex + +++ ++ 
Thalamus + - - 
 
Table 3.1 Regional differences in ATXN3 accumulation in SCA3 knock-in mouse 
brain. One-year-old Q82/Q6 mice (n=3) were immunohistochemically stained for 
ATXN3.  For diffuse nuclear staining, increasing + numbers indicate neurons with denser 
nuclear staining of Atxn3. For intranuclear and extranuclear inclusions, increasing + 
numbers indicate higher frequency of inclusions. Regions in knock-in mice that are 
indistinguishable from wild-type mice are indicated by -. 
 
Figure 3.6 Examples of scoring ATXN3 accumulation in an immunohistochemically 





Figure 3.7 ATXN3 solubility and aggregation in different brain regions of Q82/Q6 
mice. (A) 10% SDS-PAGE of soluble lysates from hindbrain and hippocampus. (B) 2% 





Figure 3.8 Alternative splicing of the mutant Atxn3 transcript is enhanced in SCA3 
knock-in mice. (A) Diagram of 3’ alternative splicing of the human ATXN3 transcript, 
showing the 10 exon-containing ATXN3 transcript (right) generated from retention of 
intron 10, which encodes a hydrophobic segment that may accelerate mutant ATXN3 
aggregation. (B) RNA-sequencing on the pons of Q82/Q82 mice shows elevated reads in 
intron 10 following the CAG repeat-containing exon 10. Genomic sequence near the end 
of the reads in intron 10 (boxed) contains a putative polyadenylation (polyA) site 
ATTAAA (underlined). (C) 3’ RACE in a Q82/Q6 mouse amplified a 300 bp band 
containing this putative polyA site (underlined) followed by a polyA tail (black, bold). 
(D) Wild-type and homozygous Q82/Q82 mice showed similar frequency of sequencing 
reads in exon 11 and the 3’ UTR of the SCA3 knock-in mice. (E) Levels of predicted 
full-length Atxn3 transcript from the RNA-sequencing (FPKMs) do not significantly 
differ between wild-type (n=7) and Q82/Q82 mice (n=7). Graph represents mean plus 






Figure 3.9 The mutant Atxn3 transcript in SCA3 knock-in mice does not exhibit 
obvious abnormalities outside the exon 10-intron 10 junction. Reads across the full 
Atxn3 transcript did not show consistent differences between representative wild-type and 
Q82/Q82 mice outside of the exon 10 – intron 10 junction (*), which shows dramatically 
elevated reads. The reads in intron 9 (~) do not consistently appear in other SCA3 knock-

















Figure 3.10 Expression of 10 exon Atxn3/ATXN3 transcript in SCA3 mouse models 
and SCA3 human fibroblasts. (A) Diagram of 10 exon ATXN3/Atxn3 (ATXN3/Atxn3-
10e) transcript and arrows indicating location of primer pairs used for quantitative PCR 
(qRT-PCR) and non-quantitative PCR (PCR) on reversed-transcribed RNA. (B) Atxn3-
10e transcript is highly upregulated (~8-fold) while total Atxn3 transcript is only 
modestly upregulated (~1.5-fold) in heterozygous SCA3 knock-in mice (n=3). (C) 
ATXN3-10e transcript is also upregulated (~2-fold) in YAC mice expressing the full 
human ATXN3 gene with 84 CAG repeats (YAC84Q, n=4) compared to 15 CAG repeats 
(YAC15Q, n=4). (D) ATXN3-10e transcript levels in SCA3 fibroblasts (n=6) did not 
significantly differ from non-disease control fibroblasts (n=4). qRT-PCR in B, C, and D 
were normalized to Gapdh, TRIP11, and ACTB, respectively. (E) PCR reveals the 
presence of mutant Atxn3-10e cDNA in SCA3 knock-in mice only. (F, G) PCR shows 
expanded and non-expanded ATXN3-10e in both YAC mouse lines, all SCA3 fibroblast 
lines, and three of four non-disease control fibroblast lines. Amplification of ATXN3 
exon 7 to exon 11 indicates the presence of ATXN3-11e in all fibroblast lines. Graphs 





Isoform-driven aggregation of the polyglutamine disease 
protein ATXN3 elicits early transcriptional changes in the 
brain 
4.1 Abstract 
Polyglutamine-encoding CAG repeat expansions cause at least nine different 
neurodegenerative diseases, all of which are associated with aggregation of the respective 
disease proteins. The role of protein misfolding and aggregation in disease pathogenesis, 
however, remains uncertain. To address this issue, we utilized newly developed knock-in 
mouse models of Spinocerebellar Ataxia type 3 (SCA3) that display differential splicing 
of the mutant Atxn3 disease gene transcript, resulting in different degrees of aggregation. 
Differential carboxy-terminal splicing markedly alters mutant ATXN3 aggregation in the 
brain of knock-in mice, with expression of a minor splice isoform accelerating 
aggregation of mutant ATXN3 and expression of a major splice isoform resulting in 
soluble mutant ATXN3. To determine whether transcriptional dysregulation, a common 
molecular feature of polyQ diseases, correlates with disease protein aggregation, we 
performed RNA-sequencing analysis in SCA3 knock-in mice and additional SCA3 
mouse models displaying differing degrees of aggregation.  In SCA3 mice, an altered 
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gene expression landscape correlated closely with degree of aggregation, with an 
unexpectedly high number of transcriptional changes predicted in oligodendrocytes. The 
encoded protein of one notably increased transcript, ACY3, was similarly increased in 
SCA3 disease brain, suggesting that similar transcriptional changes occur in the human 
disease. Finally, by utilizing Cre-recombinase’s binding to a LoxP site in the mutant 
Atxn3 locus, , we were simultaneously able to alter Atxn3 splicing, increase ATXN3 
solubility and reduce aggregate pathology, along with predicted gene expression changes.  
In summary, our findings delineate a clear relationship between mutant Atxn3 splicing, 
ATXN3 aggregation, and early transcriptional changes in vivo. These findings support a 
pathogenic role for protein misfolding and aggregation in polyglutamine disease that may 
be critically influenced by disease gene splicing.  
4.2 Introduction 
Polyglutamine (polyQ) diseases are caused by abnormally long glutamine 
stretches encoded by CAG repeat expansions in the respective disease genes. Like many 
other neurodegenerative disorders, polyQ diseases are characterized by the accumulation 
and aggregation of misfolded disease proteins (4). In the nine known polyQ diseases 
including Spinocerebellar ataxia type 3 (SCA3), the clearest evidence of this process is 
the appearance of ubiquitin-positive neuronal inclusions containing the disease protein 
and other sequestered proteins (6, 100). An unresolved question, however, is the extent to 
which the aggregation propensity of expanded polyQ proteins, and aggregates 
themselves, contribute to disease pathogenesis. In multiple studies, inclusions are not 
correlated with toxicity and have been interpreted as protective to cells (35–38), yet 
factors that reduce polyQ disease protein aggregation, such as molecular chaperones, 
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often correlate with improved phenotypes in disease models (168, 185–187). Broadly 
acting cellular factors like chaperones, however, may exert beneficial effects independent 
of the polyQ disease protein.  
One route to address the role of aggregation propensity in disease is to explore the 
consequences of expressing alternative disease protein isoforms that differ in 
aggregation. Alternative splicing of ATXN3, the disease gene in SCA3, can generate a 
diversity of ATXN3 isoforms (108).  Among these are two commonly studied isoforms: a 
major, full-length 11-exon containing transcript (ATXN3-11e, RefSeq NM_004993) (107) 
and a minor, 10-exon containing transcript lacking the 11th exon (ATXN3-10e, RefSeq 
S75313) (98). These two isoforms differ only in a small segment of the carboxy-terminus 
(Figure 4.1A). The ATXN3-10e transcript, which was the first reported isoform in SCA3, 
retains the intron following the CAG repeat-containing exon 10 and results in a more 
hydrophic carboxy-terminus that likely increases ATXN3 aggregation propensity (109). 
The extent to which differential expression of these two ATXN3 isoforms contributes to 
disease protein aggregation and disease pathogenesis is unknown. We therefore sought to 
address two key questions: Does differential expression of ATXN3 isoforms contribute to 
disease protein accumulation and aggregation in brain? And does the aggregation 
propensity of a polyQ-expanded isoform contribute to disease pathogenesis?  
To address these questions, we investigated parallel SCA3 knock-in mouse 
models that differ in alternative splicing of the mutant Atxn3 gene. In addition to the 
SCA3 knock-in mice discussed in Chapter 3 that preferentially express the aggregation-
prone isoform, we isolated a variant SCA3 knock-in mouse line that predominantly 
expresses the full-length, major splice isoform of mutant ATXN3 that is less prone to 
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aggregate. The existence of two lines expressing physiological levels of the disease gene 
with nearly identical polyQ expansions, yet differing in isoform expression, presented us 
with a rare opportunity to compare the effect of expressing different ATXN3 isoforms on 
disease protein aggregation and its downstream consequences. Because transcriptional 
dysregulation is a common feature of polyQ diseases and  likely contributes to disease 
processes (53), we carried out comparative transcriptional profiling in the nervous system 
of these knock-in lines and other SCA3 mouse models to identify molecular correlates of 
ATXN3 aggregation. Our findings shed light both on the role of alternative splicing in 
disease protein aggregation and on the potential contribution of aggregation to 
transcriptional dysregulation in SCA3 and perhaps other polyQ disorders. 
4.3 Results 
4.3.1 Distinct SCA3 knock-in lines express different mutant Atxn3 transcripts  
Alternative mutant Atxn3 transcripts expressed in distinct SCA3 knock-in mouse 
lines. For the current study we used SCA3 knock-in mice generated by homologous 
recombination, in which the endogenous Atxn3 exon 10 was replaced with a mutant exon 
10 harboring an expanded (82) CAG repeat (Chapter 3). We reported that SCA3 knock-in 
(Q82) mice robustly express the Atxn3-10e transcript and exhibit low levels of soluble 
mutant ATXN3, with a correspondingly high burden of aggregated mutant ATXN3 in the 
brain. In generating the SCA3 knock-in colony, we serendipitously identified a knock-in 
mouse variant that expresses comparatively high levels of soluble mutant ATXN3 despite 
having a nearly identical CAG repeat expansion. This more soluble ATXN3 phenotype 
segregated with the mutant allele and was maintained in subsequent generations, allowing 
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us to selectively breed a “variant” SCA3 knock-in line (Q82V mice) that could be studied 
in parallel to Q82 mice.   
Western blot analysis (Figure 4.1B) demonstrated that heterozygous Q82V/Q6 
mice express higher levels of soluble mutant ATXN3 in brain than do heterozygous 
Q82/Q6 mice.  As in other polyQ disease models (80, 81), repeat expansion lengths vary 
slightly from animal to animal in both lines due to mild repeat instability, but these subtle 
differences in repeat length did not correlate with or explain this difference in solubility. 
To explore the molecular basis of this difference, we performed non-quantitative PCR on 
reverse-transcribed RNA (RT-PCR) to examine different Atxn3 isoform transcripts in the 
brain. The aggregation-prone ATXN3-10e isoform was expressed in Q82/Q6 mice, as 
reported in Chapter 3, but not in Q82V/Q6 or wild-type mice (Figure 4.1C). In contrast, 
the full-length Atxn3-11e isoform was readily detected in Q82V/Q6 mice but not in 
Q82/Q6 mice (Figure 4.1C). Quantitative PCR on the same samples confirmed higher 
levels of Atxn3-10e transcript in Q82/Q6 mice (Figure 4.1D).  
To determine if the two SCA3 knock-in lines express mutant Atxn3 transcripts at 
similar endogenous levels, we calculated transcript levels using RNA-sequencing (RNA-
seq) reads from the pons of wild-type, Q82/Q6, and Q82V/Q6 mice. Total Atxn3 
transcripts are elevated ~2-fold in Q82/Q6 mice, whereas Atxn3-11e transcript levels are 
equal across genotypes (Figure 4.1E), suggesting that Q82/Q6 mice express mutant 
Atxn3-11e transcript in addition to mutant Atxn3-10e transcript. These results indicate 
approximately physiological expression of different mutant Atxn3 transcripts in SCA3 
knock-in lines with the Q82 line expressing more ATXN3.   
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We have not yet identified a genetic difference that delineates the two different 
SCA3 knock-in mouse lines. Sequencing of ~8,000 base pairs in homozygous Q82/Q82 
and Q82V/Q82V mice showed no differences in the sequenced regions, which spanned 
most of intron 9 including the FRT site, and all of Atxn3 exon 10, intron 10 and exon 11. 
In both lines we confirmed the presence of a LoxP site immediately upstream of the FRT 
site, included in the original targeting construct. Later in this study we exploit this LoxP 
site to convert Q82 mice to a phenotype similar to that of Q82V mice. We also cloned 
and sequenced the mutant Atxn3-10e and Atxn3-11e cDNA expressed in the respective 
homozygous SCA3 knock-in mice, and found no sequence differences apart from the 
alternatively spliced exons preferentially expressed in the two lines (not shown).  
In summary, we isolated two distinct SCA3 knock-in lines that differentially 
express, from the endogenous Atxn3 locus, mutant Atxn3 transcripts encoding two 
ATXN3 isoforms with alternative carboxy-termini predicted to differ in solubility (Figure 
4.2). These mice provide an ideal opportunity to investigate the pathophysiological 
consequences of altered mutant ATXN3 isoform expression on disease protein 
accumulation and aggregation.  
4.3.2 ATXN3 accumulation in neuronal nuclei and aggregation differs in the two 
SCA3 knock-in lines 
To determine if endogenous expression of the different isoforms leads to 
differences in ATXN3 accumulation in the nervous system, we performed 
immunohistochemical staining (IHC) for ATXN3 on one-year-old SCA3 knock-in brains. 
Q82/Q6 mice show robust intranuclear ATXN3 accumulation, both diffuse and punctate, 
as well as larger inclusions in neurons, both intranuclear and extranuclear. In contrast, 
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ATXN3 immunostaining in Q82V/Q6 mice showed no aggregate pathology and was 
indistinguishable from that of wild-type mice (Figure 4.3A). To identify biochemical 
differences in aggregation, we immunoprecipitated ATXN3 from both lines, resolved the 
eluted immunoprecipitates on polyacrylamide gradient gels, and immunoblotted for 
ATXN3. Compared to Q82V/Q6 mice, Q82/Q6 mice showed increased levels of high 
molecular weight ATXN3 species with correspondingly lower levels of soluble ATXN3 
monomer (Figure 4.3B).  
As reported in Chapter 3, aggregation-positive Q82/Q6 mice do not develop 
motor abnormalities. Conceivably, the higher levels of soluble mutant ATXN3 in Q82V 
mice could accelerate a behavioral phenotype. Thus, we assessed motor performance in 
aged (53-60 week old) SCA3 knock-in mice from both lines. Neither Q82/Q6 nor 
Q82V/Q6 mice showed deficits on any motor tasks compared to wild-type mice (Figure 
4.3 C-F). Q82/Q6 mice tend to be slightly smaller than wild-type or Q82V/Q6 mice 
(Figure 4.3E and F), but otherwise appear healthy.  
To exclude the possibility that the increased ATXN3 aggregation in Q82/Q6 mice 
is driven primarily by its ~2-fold increase in overall Atxn3 transcript levels, we generated 
homozygous Q82V/Q82V mice containing two mutant alleles. These mice show an even 
higher level of soluble mutant ATXN3 (Figure 4.4A) yet still relatively little ATXN3 
accumulation and aggregation in the brain. Even at one year of age, Q82V/Q82V mice 
show minimal ATXN3 diffuse nuclear accumulation and ATXN3 puncta by IHC 
compared to age-matched Q82/Q6 mice (Figure 4.4B). An exception is that, upon aging, 
Q82V/Q82V mice begin to exhibit large extranuclear aggregates in the hippocampus, 
reminiscent of the hippocampal aggregate in heterozygous Q82/Q6 mice. Blinded scoring 
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of aggregate pathology in the pons and hippocampus of SCA3 knock-in mice confirmed 
robust ATXN3 aggregation in Q82/Q6 mice, some in Q82V/Q82V mice, and none in 
Q82V/Q6 mice (Figure 4.4C).  
In further confirming the differing aggregation propensities of the different SCA3 
knock-in lines, IHC of a ~8-week-old Q82/Q82 mouse showed enhanced nuclear 
accumulation of ATXN3 in the DCN, while a Q82V/Q82V showed no nuclear 
accumulation (Figure 4.4D). These differences in accumulation correlated with differing 
relative expression of Atxn3-10e in the same mice (Figure 4.4E). Together, these results 
establish that expression of the mutant ATXN3-10e isoform is associated with increased 
ATXN3 aggregation and nuclear accumulation compared to equivalent expression of the 
alternative mutant isoform, ATXN3-11e. These differences may arise from the differing 
predicted solubility of ATXN3 isoforms (Figure 4.2). Therefore, alternative splicing of 
the ATXN3 disease allele may influence disease protein aggregation.   
4.3.3 Transcriptional alterations are associated with ATXN3 nuclear accumulation 
and aggregation in SCA3 mouse models 
Transcriptional dysregulation is a frequent feature of polyQ diseases (188, 189), 
and transcriptional profiling readily detects early perturbations in gene expression elicited 
by abnormal disease proteins. Accordingly, we performed RNA-seq on a vulnerable brain 
region in SCA3, the pons, in both knock-in lines as well as in an unrelated mouse model 
of SCA3 to determine whether ATXN3’s propensity to accumulate and aggregate 
correlated with specific transcriptional changes. A list of the genotypes used for RNA-seq 
and the relative abundance of ATXN3 aggregates in the pons of the various lines are 
shown in Figure 4.5A. In addition to analyzing wild-type mice, heterozygous Q82, and 
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both heterozygous and homozygous Q82V mice, we also examined two transgenic lines 
that overexpress the full human ATXN3 gene with either a normal (15Q) or pathogenic 
(84Q) CAG repeat, the YAC-15Q and YAC-84Q lines (159). YAC-84Q mice show 
robust ATXN3 accumulation and aggregation throughout the brain, including in the pons, 
while YAC-15Q mice overexpress normal human ATXN3 without aggregation or 
intranuclear accumulation (159).  
The three tested aggregation-positive lines (YAC-84Q, Q82/Q6, and Q82V/Q82V 
mice) exhibited more than 200 differentially expressed (DE) transcripts compared to 
wild-type mice, whereas the aggregation-negative lines (YAC-15Q and Q82V/Q6 mice) 
exhibited fewer than 100. Thus, the presence of aggregate-prone ATXN3 generally 
correlated with increased transcriptional changes (Figure 4.5B).  
YAC-84Q mice have the most robust aggregation profile among tested genotypes. 
To determine the extent to which altered transcripts inYAC-84Q mice are shared with 
other SCA3 mice, we generated a heat map of the differentially expressed transcripts of 
YAC-84Q using fold-change values relative to wild-type, and we compared their 
expression across all tested genotypes. The greatest number of transcriptional changes 
was shared with Q82/Q6 mice which, like YAC-84Q mice, have a high aggregate burden. 
A significant subset of changes was also shared with Q82V/Q82V mice, which manifest 
aggregates albeit fewer than the other two lines. In contrast, aggregation-negative YAC-
15Q and Q82V/Q6 mice shared relatively few changes with YAC-84Q mice and were 
most similar to wild type mice (Figure 4.5C).  
To explore the trends in transcriptional changes, we graphed the number of shared 
transcripts between the different mutant ATXN3-expressing lines (Figure 4.5D). Only 
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seven changed transcripts, all but one downregulated, were shared across all four mutant 
ATXN3-expressing lines; none of these genes were altered in YAC-15Q mice. These 
seven may represent transcripts altered by polyQ-expanded ATXN3 expression 
independent of aggregation. A comparison of transcriptional changes shared by all three 
aggregation-positive genotypes revealed a balance of 21 upregulated and 18 
downregulated genes, suggesting that ATXN3 aggregation may drive upregulation of 
certain transcripts.  
Among the differentially expressed transcripts shared between any two genotypes, 
YAC-84Q and Q82/Q6 mice share the most: 56 upregulated and 33 downregulated 
transcripts. Based on predicted cell type expression patterns (165), differentially 
expressed transcripts are preferentially expressed in oligodendrocytes (Figure 4.5E).  
Consistent with this observation, gene enrichment analysis of these 89 transcripts 
identified categories associated with myelination and oligodendrocyte development 
(Figure 4.6).  
An unanswered question in SCA3 and other polyQ diseases is the extent to which 
disease pathogenesis is associated with loss of function of the mutant protein. To address 
this, we performed a separate RNA-seq experiment on the pons of Q82/Q82 mice and 
ATXN3 knockout (ATXN3-KO) mice at ~9 weeks of age. A heat map of the same list of 
transcripts from Figure 4.5C, the differentially expressed transcripts of YAC-84Q mice, 
showed a similar transcriptional signature in Q82/Q82 mice, but not in ATXN3-KO mice 
(Figure 4.7A). A Venn diagram of the differentially expressed transcripts showed that a 
much larger number of transcripts are altered in Q82/Q82 mice than in ATXN3-KO 
mice: 570 versus 91 transcripts, respectively (Figure 4.7B). This Venn diagram reveals 
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that 22 altered transcripts are shared between Q82/Q82 and ATXN3-KO mice, 
representing a small number of transcripts that could be altered due to loss of ATXN3 
function.  In contrast, a higher number of DE transcripts, 59, are shared between 
Q82/Q82, Q82/Q6, and YAC-84Q mice (Figure 4.7C). Together, these results indicate 
that majority of transcriptional changes in aggregate-containing mice do not represent 
changes due to loss of ATXN3 function. These findings further support the view that 
aggregation in SCA3, and perhaps other polyQ diseases, drives molecular changes 
through toxic gain-of-function mechanisms.   
We validated a subset of robustly altered transcripts in an independent set of 
Q82/Q6 mice to ensure reproducibility and to identify transcripts that might serve as 
biomarkers correlating with disease protein aggregation. qRT-PCR on pontine tissue 
from six month old Q82/Q6 and Q82V/Q6 mice confirmed selective upregulation of Acy3 
and Smoc1 and selective downregulation of Agt and Dao in Q82/Q6 mice; Il33, as 
predicted by RNA-seq, was reduced in both Q82/Q6 and Q82V/Q6 mice (Figure 4.8A). 
Only one tested transcript, Polr2a, was not confirmed as significantly altered.  
Because of the robust change in Acy3 associated with ATXN3 aggregation in 
mouse models, we analyzed ACY3 at the protein level. Western blotting for ACY3 in 
hindbrain lysates confirmed that the ACY3 protein is selectively upregulated in Q82/Q6 
mice (Figure 4.8B). Importantly, ACY3 protein levels are also significantly increased in 
SCA3 human brainstem compared to Alzheimer Disease (AD) brainstem controls (Figure 
4.8C), suggesting that altered transcripts in SCA3 mice may predict congruent changes in 
human disease. In summary, the propensity of ATXN3 to accumulate in neuronal nuclei 
and form aggregates in the pons correlates with specific robust transcriptional changes.  
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4.3.4 Cre-recombinase expression in Q82 mice alters Atxn3 splicing and attendant 
aggregation  
The molecular basis for differential splicing in the two knock-in lines may center 
on the LoxP site located  ~300 bp upstream of exon 10, because we can partially convert 
the Atxn3 splicing pattern of  Q82/Q6  mice to that of Q82V/Q6  mice (Figure 4.9A). We 
expressed Cre-recombinase in Q82/Q6 mice under control of the Nestin promoter 
(Q82/Q6+Cre) to drive Cre expression in the brain and elicit alterations in Atxn3 splicing. 
Q82/Q6+Cre mice show reduced levels of Atxn3-10e transcript by RT-PCR and qRT-
PCR (Figure 4.9A and B). Consistent with this change, Q82/Q6+Cre mice also showed 
detectable Atxn3-11e transcript by RT-PCR, similar to Q82V mice (Figure 4.9A). 
Consistent with this change in splice isoform expression, we observed reduced levels of 
high molecular weight, aggregated ATXN3 and increased soluble monomeric ATXN3 in 
two month old Q82/Q6+Cre mice (Figure 4.9C). Finally, of the four robustly 
dysregulated transcripts confirmed in Q82/Q6 mice (Figure 4.8), qRT-PCR showed that 
three of these four (Acy3, Smoc1, and Agt) were significantly corrected towards wild-type 
levels in Q82/Q6+Cre mice (Figure 4.9D). These experiments provide converging 
evidence for an association between ATXN3-10e isoform expression, mutant ATXN3 
aggregation, and selective transcriptional changes presumably linked to ATXN3 
aggregation.  
4.4 Discussion 
Our comparison of SCA3 knock-in mice differentially expressing the two most 
disease-relevant ATXN3 splice isoforms illustrates that isoform expression can 
profoundly influence polyQ disease protein accumulation and aggregation.  Comparison 
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of transcriptional changes in both knock-in lines and in independent transgenic lines 
expressing normal or expanded human ATXN3 further showed that the presence of 
aggregated ATXN3 correlates with transcriptional changes in the nervous system. While 
attention in the polyQ disease field has focused on neurons, many altered brain transcripts 
in aggregate-positive mice are known to be enriched in oligodendrocytes. Among these is 
ACY3, which encodes an aminoacylase that is predicted to hydrolyze N-acetylaspartate 
(NAA) into acetate and aspartate, and this upregulation may contribute to the decreased 
level of NAA reported in SCA3 brain (190). The contribution of nonneuronal cells to 
disease pathogenesis in SCA3 and other polyQ disorders warrants further study.  
The expression of two major mutant ATXN3 isoforms studied here, identical 
except for their extreme carboxy-termini, leads to marked differences in ATXN3 
accumulation and aggregation in vivo. Just as expressing polyQ fragments of full-length 
disease proteins can accelerate disease pathogenesis (23, 26), even a single exon 
difference in polyQ disease protein isoforms can markedly alter disease protein 
accumulation in the brain. Furthermore, our findings indicate that the diffuse nuclear 
accumulation of mutant ATXN3 is associated with its aggregation propensity. 
Importantly, an expanded polyQ tract in the disease range is not sufficient to drive 
ATXN3 into the nucleus in vivo. These results further underscore the importance of 
protein context in the polyQ diseases to influence disease pathogenesis.  
The relatively low-level of expression from the endogenous Atxn3 locus in the 
knock-in mice may have aided our ability to capture relatively subtle differences in 
ATXN3 isoform solubility. The human and mouse ATXN3 isoforms are predicted to 
show differences in solubility based on their amino acid composition (Figure 4.2). 
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However, overexpression of the mutant mouse ATXN3 in cell culture did not reveal 
dramatic differences in puncta and inclusion formation between the two different 
isoforms with similar polyQ lengths (Figure 4.10).  
Efforts to identify the presumed genetic difference that drives differential Atxn3 
splicing in the Q82 and Q82V lines are ongoing. Intriguingly, both the SCA3 knock-in 
lines were generated from one founder mouse. This founder was crossed with a FLPe 
transgenic mouse, generating two F1 (FLPe-expressing) SCA3 knock-in mice that were 
further bred with wild-type mice to generate F2 mice harboring the CAG expansion in 
Atxn3 with the Neo cassette removed (Figure 4.11A). We retrospectively examined 
protein and brain from these two F1 mice and found no differences in solubility between 
the two lines (Figure 4.11B). Moreover, RT-PCR revealed Atxn3-10e and Atxn3-11e 
transcripts at similar levels in both mice (Figure 4.11C). These results, together, suggest 
that the Q82 and Q82V lines appeared subsequent to the removal of the Neo cassette. We 
have not yet examined F2 mice to test this hypothesis.  
The close segregation of this difference with the mutant Atxn3 allele, persisting 
even in homozygous mice, implies a cis-acting factor. To rule out a potentially protective 
trans-acting factor in the Q82V line that can rescue ATXN3 aggregation, we generated a 
“hybrid” homozygous Q82V/Q82 mouse. IHC of this mouse at ~12 weeks did not show 
increased or decreased nuclear ATXN3 or inclusion formation in the brainstem or 
hippocampus (Figure 4.11D). Western blotting of this mouse also segregated two distinct 
mutant ATXN3 bands with differing intensities (Figure 4.11E), further supporting the 
possibility that the knock-in lines differ with respect to a cis-acting element at the Atxn3 
gene. However, sequestration of the more soluble ATXN3 species by the aggregation-
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prone ATXN3 species generated by the Q82 mouse may confound this interpretation. 
These findings are preliminary and must be repeated, but still exclude the possibility that 
a trans-acting factor in the Q82V line rescues ATXN3 aggregation. We are currently 
performing whole genome sequencing to identify possible mutations that explain the 
differences between the two lines. 
The ability of coexpressed Cre-recombinase to partially convert the splicing 
pattern of Q82 mice to that of Q82V mice further supports the view that the different 
molecular phenotypes of the two lines directly reflect different ATXN3 isoform 
expression. We speculate that Cre-recombinase may act by binding the single LoxP 
sequence, potentially altering kinetics of Atxn3 transcription, thereby affecting splicing 
(183). The ability of Cre-recombinase to drive these phenomena indicates that the Q82 
mice resemble a “conditional” mouse in which aggregation could be manipulated in 
different cell-types. One could exploit this to address the extent to which ATXN3 
aggregation drives transcriptional changes in neurons versus non-neuronal cells through 
cell-autonomous mechanisms.  
Although the reduced solubility of the polyQ expanded disease protein likely 
contributes to disease pathogenesis, isolating the disease protein species responsible for 
this toxicity in vivo remains an active area of pursuit. The aggregation propensity of 
disease protein drives the formation of intranuclear puncta/inclusions and biochemically 
insoluble aggregate species associated with disease. These easily visualized structures 
themselves may not be directly toxic and do not exclude the pathogenic role of 
monomeric or oligomeric polyQ protein species upstream in the aggregation cascade that 
are more difficult to detect (11, 42, 46). We suggest that the inclusions and aggregates in 
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vivo represent disease biomarkers that reflect the overall increased presence of abnormal 
disease protein, including both toxic and non-toxic conformers.  Ongoing studies aim to 
identify levels of polyQ disease protein conformers in vivo that best predict toxicity. At 
present, therapies to reduce the aggregate burden should remain a viable approach, 
provided that therapies primarily do so by improving disease protein folding or clearance.  
Our findings support the notion that transcriptional alterations reflect disease-
associated processes imposed by disease protein accumulation and aggregation. 
Accordingly, only SCA3 mouse models showing signs of aggregation also shared robust 
transcriptional changes. In contrast, high levels of soluble, expanded ATXN3 in Q82V 
mice were not sufficient to drive the early transcriptional changes seen in ATXN3 
aggregate-positive mice, and overexpression of nonexpanded ATXN3 in YAC-15Q mice 
caused almost no transcriptional perturbation. Moreover, ATXN3-KO mice did not show 
much overlap with ATXN3 aggregation-associated transcriptional profiles. Studies from 
models of HD and SCA3 have shown that treatments that improve disease phenotypes 
correlate with corrected transcriptional changes (191–193). Our findings are particularly 
novel in establishing that, for mutant ATXN3 isoforms harboring the same polyQ repeat 
length, the propensity for ATXN3 to accumulate and aggregate most directly correlates 
with an altered transcriptional signature in vivo. These transcriptional changes 
conceivably occur alongside or may even directly connect with pathways that drive 
toxicity. However, a lack of neurotoxic readouts in these SCA3 mouse models limits 
conclusions we can draw about causal links between disease protein aggregation, 
transcriptional changes, and toxicity. The future identification of neuropathological 
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abnormalities that coincide with disease protein aggregation in the SCA3 mouse models 
would be informative.  
Increasing evidence supports glial contributions to polyQ disease (194). In SCA7, 
for example, mutant ATXN7 drives dysfunction of Bergmann glia that ultimately drives 
Purkinje neuron dysfunction and death (195, 196). Recently, a HD knock-in mouse 
model was reported to exhibit early myelination defects potentially precipitated by 
altered oligodendrocyte differentiation (148). Another recent study showed that 
expressing mutant HTT in oligodendrocytes alone is sufficient to induce demyelination 
and behavioral abnormalities in mice (197). Oligodendrocyte dysfunction is also featured 
in ALS (198), in which the expression of aggregation-prone mutant SOD1 in 
oligodendrocyte progenitors contributes to disease onset in a mouse model (199). Our 
analysis of transcriptional changes in SCA3 mouse models showed that the majority of 
altered transcripts are most highly expressed in oligodendrocytes, but the process that 
driving this is unclear. The transcriptional profile probably does not reflect changes in 
oligodendrocyte number since the identified oligodendrocyte-associated transcripts in 
SCA3 mice include large portions of elevated and reduced transcripts. Although we did 
not observe clear nuclear ATXN3 accumulation or aggregation in oligodendrocytes by 
immunofluorescence, small ATXN3 oligomers and microaggregates may drive 
transcriptional changes cell-autonomously. 
While oligodendrocyte pathology has not been closely studied in SCA3, the 
human disease exhibits clear white matter abnormalities. Magnetic resonance imaging 
(MRI) of SCA3 brains have shown significant reduction in pontine white matter that 
correlates with clinical disease severity (200, 201). Outside the CNS, cytoplasmic 
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ATXN3 aggregates have been detected in Schwann cells of SCA3 disease tissue (202), 
andYAC-84Q mice exhibit diminished myelination of the sciatic nerve (159).  SCA3 
knock-in mice may not practically allow examination of demyelination in the pons, 
where myelinated fibers are particularly heterogeneous and difficult to quantify, but 
further analysis of aged YAC-84Q and homozygous Q82 mice may help establish 
functional consequences of dysregulated oligodendrocyte transcripts.  
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Figure 4.1 SCA3 knock-in lines express different Atxn3 transcripts. (A) The human 
ATXN3 gene expressed at least two different transcripts: a full-length ATXN3 transcript 
with 11 exons (ATXN3-11e, right) and alternate transcript generated by retaining intron 
10 (ATXN3-10e, left), which encodes a different carboxy-terminus that makes it more 
aggregation-prone. This chapter shows that the Atxn3-10e transcript in SCA3 knock-in 
mice is associated with accelerated disease protein aggregation in the brain and may 
accelerate pathogenesis. (B) Western blot analysis of brain shows that “variant” SCA3 
knock-in mice (Q82V/Q6) express high soluble levels of mutant ATXN3 compared to 
our previously reported Q82/Q6 mice despite  harboring similar CAG repeat lengths. (C) 
Non-quantitative RT-PCR amplified mutant Atxn3-10e cDNA in only Q82/Q6 mice and 
full-length mutant Atxn3 cDNA only in Q82V/Q6 mice. (D)Quantitative RT-PCR (qRT-
PCR, left) with primers specific to Atxn3-10e confirmed enhanced relative expression in 
Q82/Q6 mice (E) Calculated transcript levels from RNA-seq reads (FPKM, right) of the 
pons showed ~2-fold increase in total Atxn3 in Q82/Q6 mice compared to wild-type or 
Q82V/Q6 mice, but equal Atxn3-11e between all genotypes. Arrows: wild-type ATXN3; 









Figure 4.2. Human and murine ATXN3-10e isoforms are predicted to have greater 
hydrophobicity. Protein sequences encoded from ATXN3/Atxn3 Exon 10/11 and Exon 
10/intron 10 are shown above. Calculating the grand average of hydropathicity (GRAVY) 
for the full-length protein or differentially encoded segment showed a higher positive 









Figure 4.3 ATXN3 aggregation is increased in SCA3 knock-in mice expressing 
Atxn3-10e. (A) Immunohistochemical staining (IHC) for ATXN3 in ~1-year-old brains 
shows prominent nuclear accumulation and intraneuronal inclusions throughout the brain 
in Q82/Q6 mice, including in the pons, deep cerebellar nuclei (DCN), in hippocampus 
(CA1 and stratum radiatum, StRad),  but not in Q82V/Q6 mice. Scale bar = 10mm. (B)  
ATXN3 immunoprecipitated from  brain lysates,  resolved on a polyacrylamide gradient 
gel and probed for ATXN3, show reduced high molecular weight (HMW) ATXN3 
species in Q82V/Q6 mice compared to Q82/Q6 mice with a corresponding increase in 
soluble ATXN3 (arrowhead).  Quantification of the HMW ATXN3 is shown on the right. 
(C-F) 53 to 60-week-old mice showed no differences in motor performance on rotarod 
(C), balance beam (D), or open field (E). Genotypes included wild-type (n=19), Q82/Q6 
(n=19), and Q82V/Q6 (n=18) mice. Female Q82/Q6 mice showed a slightly reduced 







Figure 4.4. ATXN3 aggregation remains low in homozygous variant SCA3 knock-in 
mice. (A) Western blot analysis of Q82V/Q82V mouse brain show higher levels of 
soluble mutant ATXN3 (arrowhead) compared to a Q82/Q6 mouse. Arrow: wild-type 
ATXN3. (B) IHC of ATXN3 in a ~48-week-old homozygous Q82V/Q82V still show 
markedly reduced nuclear accumulation and inclusion formation in the brainstem and 
hippocampus compared to an age-matched Q82/Q6 mouse. Q82V/Q82V mice contain 
large extranuclear inclusions in the hippocampus similar to Q82/Q6 mice. Scale bar = 
10m (C) Table summarizing the aggregate amount scored in different regions of n=3 
SCA3 knock-in mice at ~48 weeks of age. (D) IHC for ATXN3 mice shows further 
enhanced nuclear ATXN3 in the DCN of a ~8-week-old Q82/Q82 mouse and no apparent 
nuclear accumulation in an age-matched Q82V/Q82V mouse. (E) qRT-PCR of hindbrain 
RNA of the mice from (D) showed ATXN3 nuclear accumulation correlated with relative 





Figure 4.5. Increased aggregation-propensity of ATXN3 associates with robust 
distinct transcriptional changes in the pons. (A) Summary of the genotypes used for 
RNA-seq and the relative amount of ATXN3 aggregation in the brain of each mouse, 
including transgenic SCA3 YAC mice expressing ATXN3 from full-length ATXN3 gene 
with 15 (YAC-Q15) or 84 (YAC-Q84) CAG repeats. Transcripts differentially expressed 
(DE) from wild-type were obtained from DESeq. (B) Mice containing ATXN3 
aggregates (Q82/Q6, Q82V/Q82V, and YAC-Q84) exhibit a higher number of DE 
transcripts than mice with little or no aggregates (Q82V/Q6 and YAC-Q15). (C) 
Clustered heat map of the ~100 most significant DE transcripts in YACQ84 mice parallel 
the changes in Q82/Q6, and to a lesser extent, in Q82V/Q6 mice. (D) Graphing shared 
DE transcripts between different genotypes shows an increasing amount of upregulated 
transcripts associated with mice with increasing ATXN3 aggregation. (E) DE transcripts 
shared in Q82/Q6 and YAC-Q84 mice are expressed in several cell-types in the brain, but 





Figure 4.6 Transcripts associated with ATXN3 aggregation are enriched in 
biological processes linked to oligodendrocytes. Left, Venn diagram showing DE 
transcripts shared between different genotypes. Q82/Q6 and YAC-84Q mice share the 
highest number transcripts among these comparisons. These transcripts were subjected to 
gene enrichment analysis, shown right. Both upregulated (red) and downregulated (green) 










Figure 4.7 Transcriptional alterations in Q82/Q82 mice are minimally associated 
with ATXN3 loss of function. (A) Heat map of the same transcripts from Figure 4.4C 
shows similar alterations in pontine RNA-seq of 9-week-old Q82/Q82 mice (n=3), but 
not in ATXN3 knockout (ATXN3-KO) mice (n=3). (B) Venn diagram showing a large 
number of DE transcripts in Q82/Q82 with 22 transcripts shared with ATXN-KO mice. 









Figure 4.8. Validation of altered transcripts in Q82 versus Q82V SCA3 knock-in 
mice. (A) qRT-PCR of several DE transcripts including some upregulated (left: Acy3 , 
Polr2a, and Smoc1) and downregulated  (right: Agt, Dao, and Il33) in ~6-month-old 
SCA3 knock-in mice (n=5). (B) Western blot of ACY3 in ~1-year-old SCA3 knock-in 
mice hindbrain and with quantification shown on the right. (C) Western blot of ACY3 in 
Alzheimer disease (AD) and SCA3 brainstem lysates with quantification shown on the 













Figure 4.9. Expression of Cre recombinase in the brain of Q82/Q6 mice reduces 
Atxn3-10e expression, ATXN3 aggregation, and transcriptional changes. (A) 
Schematic of Q82 knock-in locus showing a single LoxP site in intron 9 that can bind Cre 
recombinase. Below, RT-PCR of the pons showed reduced Atxn3-10e expression and 
recovery of Atxn3-11e signal in Q82/Q6 mice expressing Cre-recombinase under the 
Nestin promoter (Q82/Q6+Cre). (B) qRT-PCR of the same samples showed significant 
reduction Atxn3-10e and total (exon 10-containing) Atxn3 transcript in Q82/Q6+Cre mice 
(n=3). (C) Western blotting of brain lysates IP-ed for Atxn3 and resolved on a 3-12% 
Tris-Acetate gel showed reduced aggregation of ATXN3 in Q82/Q6+Cre mice relative to 
Q82/Q6 mice that coincided with increased soluble monomeric mutant ATXN3 . (D) 
qRT-PCR on pons of ~2-month-old Q82/Q6+Cre mice (n=3) showed correction toward 
wild-type levels of three of four tested transcripts (Acy3, Smoc1, and Agt) relative to 








Figure 4.10. Overexpressing mutant ATXN3 isoforms in cell culture did not show 
differences in puncta formation. Left, western blot of Atxn3 from pcDNA 3.1 shows 
expression of nonexpanded ATXN3 (Wild-type), mouse Q74 ATXN3-11e (Q74-FL), and 
mouse Q71 ATXN3-10e (Q71-int10) in HEK293 cells. Right, average number of puncta 











Figure 4.11 Identifying the  origin and heritability of the different mutant Atxn3 
phenotypes in SCA3 knock-in mice. (A) Simplified pedigree of the SCA3 knock-in 
lines, which were generated by breeding the founder with a FLPe transgenic mouse. (B, 
C) F1 (FLPe expressing) SCA3 knock-in mice did not show differences in mutant Atxn3 
solubility and show expression of both mutant Atxn3 transcripts by RT-PCR. (D) 
Preliminary experiments showed that generating a hybrid Q82V/Q82 mouse did not 
markedly increase or decrease ATXN 3 aggregation relative to an age-matched Q82/Q6 
mouse (~12 weeks).  (E) Western blot of the Q82V/Q82 separated two distinct ATXN3 















Conclusions and future directions 
 
 The results described in this dissertation lead to four main conclusions. Firstly, the 
Q82 SCA3 knock-in mouse model represents a significant new disease model for the 
field that exhibits key molecular features of disease, including robust disease protein 
aggregation and alternative splicing of the mutant transcript. Secondly, alternative 
splicing of ATXN3 can markedly affect mutant ATXN3 aggregation in the brain. Thirdly, 
the aggregation of mutant ATXN3 correlates with an early and robust transcriptional 
signature in the brain. And finally, the altered transcriptional profile of SCA3 mice 
containing ATXN3 aggregates alerts us to the potential involvement of oligodendrocytes 
in disease pathogenesis. Together, the main findings of this thesis suggest that the 
misfolding tendency of polyQ disease protein is a, if not the, driving force in disease. 
Nevertheless, substantial gaps remain in our understanding of SCA3 and the polyQ 
diseases as we strive for new therapies. In this section I outline some of the opportunities 
moving forward from this work.  
5.1 Diverse uses of the SCA3 knock-in mice and extended 
characterization 
 
 No SCA3 knock-in mouse had been reported before 2014. By the end of 2015, the 
field will likely have three SCA3 knock-in mice: our two SCA3 knock-in mouse lines, 
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one of which is already published (151), and a chimeric exon 10/11 SCA3 knock-in 
mouse model reported by Switonski et al.(152). Our published Q82 SCA3 knock-in line 
is already available to the public through Jackson Laboratories. We plan to publish the 
Q82 variant line described in chapter 4 shortly. Scientists will be able to utilize one or 
more of these knock-in mice to explore early molecular changes, alterations to native 
interactors, and the potential contribution of loss of function effects to SCA3 disease 
pathogenesis. Among the available SCA3 knock-in mice, the Q82 line shows the most 
early and robust mutant ATXN3 aggregation throughout the CNS and will likely be the 
most useful for studying disease processes.  
 Future characterization of behavioral and neuropathological changes in the Q82 
and Q82V lines could establish the detrimental effects of mutant ATXN3 expression and 
aggregation. I found no differences between one-year-old heterozygous knock-in lines on 
motor testing, but homozygous knock-in mice at one year of age or older may further 
exhibit the consequences ATXN3 aggregation. I would predict that aged Q82/Q82 mice 
will weigh significantly less than age-matched wild-type and Q82V/Q82V mice, but may 
not exhibit robust differences on motor performance. However, homozygous mice should 
be further tested for other neuropathological changes including neuronal loss, gliosis, 
decreased neurotransmitter binding, synaptic/electrophysiological changes, or other 
subtle deficits that would indicate neuronal dysfunction or degeneration. In the end, 
however, the strength of the SCA3 knock-in probably lies not in studies of motor 




 Delineating the genetics between the SCA3 knock-in lines remains a high priority. 
My analysis of the pedigree of these knock-in lines suggests that the differences likely 
appeared during the removal of the Neo cassette using the FLP/FRT system, but PCR and 
Sanger sequencing of this region did not show any differences in this region. I have 
submitted tail DNA from a Q82/Q82 and a Q82V/Q82V mouse for whole genome 
sequencing to broadly assess the full Atxn3 locus. Identifying a critical genetic difference 
between the knock-in lines could inform aspects of splicing biology, including cis- and 
trans-acting factors that underlie Atxn3 splicing. Moreover, scientists would appreciate a 
report of how gene manipulation in biological models can deviate from expectations, 
especially since these techniques are pervasively used. To my knowledge, genetic 
aberrations driven by the FLP/FRT have not been documented.  
Expressing Cre recombinase in the Q82 line intriguingly substantiates my 
conclusions by recapitulating features of the Q82V line, but the mechanism that drive this 
phenomenon is unknown. I could not identify another nearby LoxP site that might 
recombine with the LoxP site in intron 9. My working hypothesis is that Cre recombinase 
simply binds the LoxP in intron 9 to alter the kinetics of RNA polymerase action at that 
junction, which could influence splicing (183). Cre recombinase binding to LoxP may 
reduce mis-splicing of Atxn3 by extending the time for splicing machinery to efficiently 
join exon 10 and 11. To test if Cre recombinase can reversibly alter splicing of Atxn3, one 
could transiently express Cre recombinase in Q82 mice under a tamoxifen-inducible 




Cre recombinase-driven differences in splicing and ATXN3 aggregation in our 
Q82 line may serendipitously help future study of ATXN3 aggregation in different cell 
types. Directing Cre recombinase to specific cell-types by driving expression under 
different promoters could be a novel way to assess both neuronal and non-neuronal 
contributions to disease. Studies in SBMA, HD, and SCA7 have provided evidence for 
non-cell-autonomous effects of the polyQ disease protein (194, 196, 203), but this is 
unexplored in SCA3. Our Q82 knock-in mouse would have the added benefit of testing 
the effects of ATXN3 aggregation in vivo without overexpression or complete deletion of 
the mutant protein. A study of this type is unprecedented in the polyQ disease field.  
A final note on the utility of SCA3 knock-in mice is its ability to test new gene-
editing technologies for study and therapy.  Nucleases engineered to specifically edit 
genomes have recently emerged as a powerful way to specifically modify genes in vivo 
(204). While these techniques are in their infancy, they could easily expand as a novel 
type of gene therapy that could apply to the polyQ disease (205). Since the goal of such a 
therapy would be to target the endogenous disease gene, polyQ disease knock-in mice 
would be ideal to test the effects of altering the disease gene in vivo. The modifications 
could include altering or removing the CAG repeat expansion or simply ablating disease 
gene expression. SCA3 is in a favorable position among polyQ diseases to silence ATXN3 
as a therapy, since ATXN3 knockout mice do not exhibit deleterious features. Therefore, 
SCA3 knock-in mice could be at the forefront in testing advanced genome editing 





5.2  ATXN3 isoforms and protein context in polyQ disease 
 
The work of this dissertation is the first to show the striking extent to which 
altering disease protein isoforms can affect disease protein aggregation in vivo. Even a 
subtle difference between ATXN3 isoforms, differing by only one exon, markedly affects 
ATXN3 aggregation in the brain. The influence of different disease protein isoforms 
could pertain to other polyQ diseases. HD knock-in mice show retention of intron 1 
following the CAG repeat-containing exon 1, resulting in the expression of a highly 
aggregation-prone exon 1 fragment (86). In SCA6, a downstream cistron within 
CACNA1A can drive the production of a C-terminal polyQ-containing fragment that may 
drive SCA6 pathogenesis (206). Our findings further argue for the exploration of even 
subtle differences in polyQ protein isoforms that could potentially influence disease. 
Alternative splicing of the disease gene has been reported for all other polyQ diseases, 
including SCA1 (207), SCA2 (208), SCA6 (209), SCA7 (210), SCA17 (211), SBMA 
(212), and DRPLA (213). Scientific understanding of the role of protein context in polyQ 
diseases would benefit from the exploration of even subtle differences exhibited by 
alternative isoforms of the disease protein.   
Future studies in SCA3 are needed to establish the relative contribution of the 
expression of human ATXN3-10e isoform in vivo. One way to address this is through 
YAC-84Q mice, which express both the ATXN3-10e and -11e transcripts. The Paulson 
lab and their collaborators together have shown that RNA interference targeting the 
3’UTR of the ATXN3 transcript dramatically reduces ATXN3 aggregation in YAC-Q84 
mice (214, 215). This silencing strategy presumably knocks down the ATXN3-11e 
isoform which contains the 3’UTR, and this was shown to abrogate ATXN3 expression 
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and aggregation. However, whether the expression of the mutant ATXN3-10e remains 
after siRNA treatment is uncertain. Selectively targeting the ATXN3-10e transcript with 
siRNA or promoting splicing to the full-length transcript with anti-sense oligonucleotides 
may also reduce ATXN3 aggregation in YAC-84Q mice, further establishing a 
pathogenic contribution of ATXN3-10e isoform.  
To explore different splice isoforms of SCA3, a recently developed human 
embryonic stem cell line (hESCs) containing a CAG expansion in ATXN3 may prove to 
be useful. This cell line, which is already being studied in the Paulson lab, can be 
differentiated into neurons and expresses mutant ATXN3 at physiological levels (not 
shown). Based on the results presented in this thesis, I expect that these cells will be 
found to express both ATXN3-10e and -11e transcripts. Moreover, hESCs can be 
modified by gene-editing (216) to directly test the consequences of altering the disease 
gene. For example, gene editing can be used to drive the selective expression of different 
ATXN3 transcripts (i.e. -10e vs. -11e) at physiological levels in differentiated neurons to 
examine their respective effects on aggregation and disease-relevant cellular pathways.  
The factors driving the mis-splicing of ATXN3 and other polyQ disease genes are 
unknown. The enhanced expression of Atxn3-10e transcript in Q82 mice first suggested a 
CAG-repeat-length-dependent process, supported with data from SCA3 YAC mice 
(Chapter 3), but its absence in Q82V mice argues that the presence of an expanded CAG 
repeat is not sufficient. CAG-dependent mis-splicing of other polyQ disease genes has 
not yet been shown to converge on a common role of CAG expansions in affecting 
splicing. Sathasivam and colleagues identified SRSF6 as a putative splicing factor that 
preferentially binds to CAG expansions (86). Testing SRSF6’s binding to disease repeats 
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in the differentially spliced SCA3 knock-in lines may reveal differences that suggest a 
SRSF6-dependent mechanism. However a higher priority is identifying the cis-acting 
genetic differences between these two lines. As more information on alternative splicing 
of different polyQ disease genes becomes available, we may begin to uncover common 
elements that regulate splicing and their roles in disease.   
5.3 Disease protein aggregation in polyQ disease pathogenesis 
 
 Along with the finding that alternative splicing can modify disease protein 
aggregation in vivo, the work in this dissertation sheds light on the pathogenic role of 
aggregation. Studies have increasingly shifted away from using aggregation as a readout 
for the pathogenic disease process with the understandable concern that the presence of 
non-toxic aggregates, or possibly even protective aggregates, may confound the results. 
Nonetheless, my view is that prominent aggregates and intraneuronal inclusions still 
serve as important biomarkers of the abnormal process of mutant protein accumulation 
with toxic properties. My findings indirectly suggest that the aggregation propensity of 
polyQ-expanded ATXN3 drives disease. However, this raises two issues that relate to 
investigating aggregation and toxicity in disease models. 
The first issue is the difficulty of establishing a causal relationship between 
aggregation and disease pathogenesis in an animal model that lacks robust behavioral or 
degenerative phenotypes. In this dissertation, I infer pathogenicity of aggregates from the 
altered transcriptional profiles of the SCA3 knock-in mice. My reasoning is that a higher 
number of transcriptional changes most likely reflects the presence of a stressful stimulus 
that perturbs the transcriptional network. Consistent with this, aggregate-containing 
SCA3 mice showed a greater number of altered transcripts than YAC-Q15 
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overexpressing nonexpanded ATXN3, Q82V/Q6 mice with non-aggregated mutant 
ATXN3, or ATXN3-KO mice, suggesting that the misfolding tendency of ATXN3 
stresses cells in some manner. These findings complement a large body of literature 
discussed in Chapter 1 that supports a clear association between aggregation and toxicity. 
The strength of my work here is in investigating this association under physiological 
conditions and without overexpression of other cellular factors, but this comes at a cost of 
easily accessible toxic phenotypes. Future studies examining other early molecular 
changes, such as electrophysiological (217), neurometabolic  (190), cytoarchitectural (i.e. 
morphology of subcellular structures) , or subtle white matter abnormalities, could further 
elucidate the role of aggregation in disease pathogenesis in the SCA3 knock-in mice. 
Furthermore, establishing additional early readouts of toxicity would also help in the 
future assessment of treatment efficacies in mouse models of disease. 
The second issue is the importance of identifying the toxic polyQ species or 
conformers that lead to neurodegeneration. One challenge is that a sufficient 
concentration of misfolded mutant polyQ protein monomers may aggregate to form both 
toxic and non-toxic polyQ protein species, thus adding difficulty to dissociating the 
relative contributions of each polyQ protein species to toxicity. To partially address this, 
Miller et al developed an antibody, 3B5H10, specific to misfolded conformations of 
polyQ monomer that predicted toxicity in cell culture (42, 46). It would be interesting to 
see if this or other conformer-specific antibodies show differences in reactivity between 
Q82 and Q82V lines to provide an additional correlate of toxicity. Antibodies or methods 
specific to toxic polyQ conformers in vivo that serve as better predictive markers or 
pathogenesis could replace aggregate burden and inclusion formation as disease markers.   
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With aggregation as a central mediator of disease, my findings support continued 
efforts to target factors that influence disease protein aggregation. For example, I have 
already discussed how alternative isoforms and proteolytic processing of the disease 
protein can affect aggregation and pathogenesis. Various post-translational modifications 
also can play important roles in aggregation, as reviewed by Pennuto et al (218), 
including ubiquitination, SUMOylation, phosphorylation, acetylation, palmitoylation, and 
transglutamination. An improved understanding of the proteostasis network has led to 
insights on quality control factors that can help refold or clear the mutant polyQ disease 
protein (168). In addition to Hsp70, different Hsp40 proteins are recognized as potent 
suppressors of mutant polyQ disease protein aggregation that may prove beneficial (219). 
Lastly, induction of autophagy has been supported as a viable therapeutic option to clear 
aggregates in the nervous system (220). With the increasing identification of key 
modifiers of aggregation, major efforts are taking place to identify pharmacological 
compounds that can act through these pathways. These therapies include protease 
(calpain) inhibitors (221), chaperone activators (222), and autophagy inducers (220). 
Moreover, future studies may reveal novel factors that can influence disease protein 
aggregation.   
5.4 Understanding transcriptional changes in polyQ disease 
 The importance of nuclear localization in driving polyQ disease toxicity in 
different disease models supports transcriptional dysregulation as a major contributor to 
disease pathogenesis.  This possibility is supported by a large body of evidence in HD 
and other polyQ diseases that have demonstrated detrimental effects of altered activity of 
specific transcription factors and the corresponding changes in expression of their 
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downstream targets. This has led to increased efforts to use gene expression profiling via 
microarray and RNA-seq, which sensitively and rapidly provide vast amounts of 
transcriptional data, to identify pathways that lead to toxicity. However, despite 
significant technological advances in transcriptional profiling and its analysis, this 
strategy still poses an immense challenge for several reasons.  
When presented with extensive transcriptional data from disease models or tissue, 
several factors complicate the interpretation of altered transcripts and their role in disease 
pathogenesis. An altered transcript in a disease model may fall under at least one of these 
categories: 1) The transcriptional change is directly detrimental, 2) it represents a neutral 
marker of a detrimental disease process, 3) it correlates with the presence of the disease 
mutation, but is unrelated to the disease process, or 4) it is a protective response to the 
disease process. Furthermore, when expression profiles are obtained from brain tissue, 
other factors must be considered: altered transcripts may reflect cell-autonomous 
mechanisms elicited by effects of the disease protein in that cell, non-cell autonomous 
responses to changes in another cell, or an epiphenomenon caused by changes in cellular 
composition of the analyzed tissue, as occurs with neuronal loss or gliosis. Finally, the 
cascade of events leading to an observed change in gene expression can be extremely 
complex and indirect, with potentially dozens of intermediate changes set forth by 
disruption of major cellular components.   
Nevertheless, a tissue-based gene expression profile provides a broad signature 
that can serve as a useful and sensitive biomarker of disease progression in mouse 
models. By analyzing multiple SCA3 mouse models in our RNA-seq datasets, we were 
able to focus attention on a specific candidate transcript associated with mutant ATXN3 
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aggregation, ACY3, and validate the observed changes in human disease tissue. A 
transcriptional profile of SCA3 human disease tissue, or of iPSCs or hESCs with the 
disease mutation, would be invaluable in assessing the validity of the SCA3 mouse 
models. Future therapeutic studies that target ATXN3 levels or aggregation in YAC-84Q 
or Q82 SCA3 knock-in mice can assess several transcripts, including ACY3, to determine 
if therapies are effective. Furthermore, transcriptional alterations, as I have shown in my 
work, can also easily be assessed presymptomatically. Therefore, testing a focused set of 
transcripts by qRT-PCR would be a time- and cost-effective way to assess disease 
progression in these mouse models.  
 Ongoing analysis of our RNA-seq data could help distill information about the 
SCA3 disease network in the brain to identify critical altered factors. The analytical 
process remains challenging, but continues to evolve with increasingly available data and 
improved computational technology. Researchers are more commonly integrating vast 
databases of information on transcriptional alterations, protein-protein interactors, 
functional biological pathways, metabolic pathways and more, to develop a complex 
disease network (223). Gene co-expression analyses are now increasingly used to sort 
transcriptional data and identify major transcriptional networks and their “hubs” in 
disease, which may represent critical transcription factors (224, 225). For example, our 
collaboration with the Guan group at the University of Michigan will make use of unique 
algorithms (226) that examine co-expression to generate a transcriptional network in 
different SCA3 mouse models to extract information on central factors that drive 
transcriptional perturbation in SCA3. The altered transcripts or factors themselves may 
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not necessarily play direct pathogenic roles, but this information can provide important 
clues to the disease process in the nervous system elicited by aggregation.  
Substantial gaps still exist in our understanding of the transcriptome, including its 
diversity and dynamic regulation in different cell types. These gaps include a poor 
understanding of the differences in alternative splicing across the transcriptome which 
could provide clues to disease processes and its effects in RNA-associated 
pathways(227); such differences can be further explored in our RNA-seq data.  In 
addition, while scientists have focused on coding transcripts in SCA3, the vast majority 
of our transcriptome is non-coding (228). Our RNA-seq data could provide a unique look 
into some non-coding RNAs that may be dysregulated in disease. Unfortunately, because 
our RNAseq selected for polyadenylated transcripts, we cannot directly examine 
microRNAs. Future studies should examine the microRNAs altered in disease in a 
directed manner, as their regulation can crucially influence aging and degenerative 
processes (229, 230). Our data can potentially be mined for alterations in polyadenylated 
long non-coding RNAs (lncRNAs). The study of lncRNAs is on the rise in 
neurodegenerative disease, with few reports in polyQ disease emerging over the last few 
years (231–234), but is unexplored in SCA3.  
5.5 Oligodendrocytes and glial contributions to polyQ disease 
 
A central goal for researchers studying neurological disease is to improve 
neuronal function, since neuronal activity and action directly dictate behavior/cognition. 
Accordingly, attention in polyQ diseases and most other neurodegenerative disorders has 
been on neurons and their dysfunction. However, a large body of evidence now supports 
the importance of non-neuronal cells in nervous system function and specific diseases 
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(235). Even beyond primary glial loss as a cause of neurological disease, as in multiple 
sclerosis, glial dysfunction can play critical roles in neurodegenerative disease and 
ultimately affect neuronal function. Therefore, an improved understanding of non-
neuronal dysfunction can lead to better insight into polyQ disease pathogenesis.  
White matter dysfunction may contribute to disease symptoms in SCA3 but 
requires further exploration. Our analysis of RNA-seq data in SCA3 mouse models 
implicates a robust transcriptional response by oligodendrocytes, the primary myelin-
producing cell of the CNS.  Previous studies using MRI of SCA3 brain have revealed 
consistent and prominent white matter abnormalities that correlate with symptoms (200, 
201), but these have not been as well characterized neuropathologically. The polyQ 
research field would benefit from improved white matter characterization in disease and 
disease mouse models to begin uncovering the consequences of myelin dysfunction.   
 A primary step to understanding oligodendrocyte dysfunction is to determine the 
factors that drive transcriptional changes in the SCA3 knock-in mice. Two main 
questions arise from our profiling data in SCA3 mice: 1) Are the transcriptional changes 
driven in oligodendrocytes cell-autonomously and 2) do the transcriptional changes 
depend on mutant ATXN3’s nuclear localization? A recent study by Huang et al showed 
that mutant HTT alters MYRF, a myelin-associated transcription factor, to alter 
transcription directly in oligodendrocytes (197). However, immunostaining for Olig2 or 
CC1, markers of oligodendrocytes, did not show clear colocalization with ATXN3 or its 
aggregates in SCA3 knock-in mouse brain. Based on cell-type specific RNA-seq 
expression data of mouse cortex (165), ATXN3 is expressed in oligodendrocytes. While 
we do not detect ATXN3 in oligodendrocytes by immunostaining, oligomers or 
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microaggregates of ATXN3 that cannot be easily visualized may still contribute to cell-
autonomous changes in oligodendrocytes. As discussed earlier, one could express Cre-
recombinase via an Olig2 promotor in the Q82 line to reduce  ATXN3 aggregation in 
oligodendrocytes to determine if alteration of Acy3 and other oligodendrocyte-associated 
transcripts are normalized. Alternatively, generating a novel mouse model of SCA3 that 
allows cell-type specific deletion of the mutant gene may prove worthwhile to delineate 
the contribution of ATXN3 aggregation in different cell types of the nervous system, as 
well as cell-autonomous and non-cell-autonomous contributions to neuronal dysfunction. 
Finally, transcriptional profiling of mouse brain with aggregation-prone mutant ATXN3 
prevented from entering the nucleus by adding an NES (52) may provide information on 
the nuclear dependence of mutant ATXN3 on eliciting transcriptional changes.  
5.6 Concluding remarks 
 The polyQ diseases and related neurodegenerative diseases pose a significant 
burden worldwide without any available disease-modifying therapies. Disease protein 
misfolding and aggregation has been recognized as a central feature of the polyQ diseases 
nearly since their discovery, and for almost as long has been a major point of debate. My 
work in this dissertation helps cement a central role for mutant ATXN3 aggregation in 
SCA3 pathogenesis, and this concept likely applies to other polyQ diseases. Dissecting 
polyQ disease pathways has proved to be complicated and challenging.  Building relevant 
disease models is a crucial step towards understanding disease and moving towards 
therapies. In this regard, mouse models of disease, and in particular knock-in mouse 
models that express endogenous levels of disease proteins, will continue to be important 
tools for exploring disease pathogenesis. My dissertation work in uncovering the 
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characteristics of novel SCA3 knock-in mouse models is a major step for future studies 
that will utilize these mice to explore disease pathways.   
Considering the incomplete understanding of these disease processes and the 
desperate need for therapies for polyQ disease, a simple and direct strategy targeting the 
mutant disease protein and its misfolding tendency remains the most sensible avenue for 
therapy.  Importantly, my work argues that the effectiveness of such strategies can be 
tested in mouse models that do not exhibit a motor phenotype. Along with disease protein 
aggregation, early transcriptional changes and other markers can help assess treatment 
efficacy in preclinical trials. My work and the works of others further support pre-
symptomatic administration of polyQ disease-modifying therapies, including those that 
reduce disease protein aggregation, to prevent or delay onset of disease. An effective 
treatment for polyQ disease would help a large number of people and would also serve as 
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